ID   RYR1_HUMAN              Reviewed;        5038 AA.
AC   P21817; Q16314; Q16368; Q9NPK1; Q9P1U4;
DT   01-MAY-1991, integrated into UniProtKB/Swiss-Prot.
DT   13-JUN-2006, sequence version 3.
DT   22-FEB-2023, entry version 240.
DE   RecName: Full=Ryanodine receptor 1;
DE            Short=RYR-1;
DE            Short=RyR1;
DE   AltName: Full=Skeletal muscle calcium release channel;
DE   AltName: Full=Skeletal muscle ryanodine receptor;
DE   AltName: Full=Skeletal muscle-type ryanodine receptor;
DE   AltName: Full=Type 1 ryanodine receptor;
GN   Name=RYR1; Synonyms=RYDR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND PARTIAL PROTEIN SEQUENCE.
RC   TISSUE=Skeletal muscle;
RX   PubMed=2298749; DOI=10.1016/s0021-9258(19)39968-5;
RA   Zorzato F., Fujii J., Otsu K., Phillips M.S., Green N.M., Lai F.A.,
RA   Meissner G., Maclennan D.H.;
RT   "Molecular cloning of cDNA encoding human and rabbit forms of the Ca2+
RT   release channel (ryanodine receptor) of skeletal muscle sarcoplasmic
RT   reticulum.";
RL   J. Biol. Chem. 265:2244-2256(1990).
RN   [2]
RP   SEQUENCE REVISION TO 2324; 2840 AND 3380, INVOLVEMENT IN MHS1, VARIANT MHS1
RP   ARG-248, AND VARIANTS CYS-471; LEU-1787; CYS-2060 AND VAL-2550.
RC   TISSUE=Muscle;
RX   PubMed=1354642; DOI=10.1016/0888-7543(92)90042-q;
RA   Gillard E.F., Otsu K., Fujii J., Duff C.L., de Leon S., Khanna V.K.,
RA   Britt B.A., Worton R.G., McLennan D.H.;
RT   "Polymorphisms and deduced amino acid substitutions in the coding sequence
RT   of the ryanodine receptor (RYR1) gene in individuals with malignant
RT   hyperthermia.";
RL   Genomics 13:1247-1254(1992).
RN   [3]
RP   SEQUENCE REVISION TO 1365-1368, VARIANT CCD HIS-2435, AND ALTERNATIVE
RP   SPLICING.
RC   TISSUE=Muscle;
RX   PubMed=8220422; DOI=10.1038/ng0993-46;
RA   Zhang Y., Chen H.S., Khanna V.K., de Leon S., Phillips M.S.,
RA   Schappert K.T., Britt B.A., Brownell A.K.W., McLennan D.H.;
RT   "A mutation in the human ryanodine receptor gene associated with central
RT   core disease.";
RL   Nat. Genet. 5:46-50(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING, AND VARIANTS
RP   ALA-1832 AND VAL-2550.
RX   PubMed=8661021; DOI=10.1006/geno.1996.0238;
RA   Phillips M.S., Fujii J., Khanna V.K., de Leon S., Yokobata K.,
RA   de Jong P.J., McLennan D.H.;
RT   "The structural organization of the human skeletal muscle ryanodine
RT   receptor (RYR1) gene.";
RL   Genomics 34:24-41(1996).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E.,
RA   Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A.,
RA   Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S.,
RA   Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A.,
RA   Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J.,
RA   Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M.,
RA   Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W.,
RA   Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V.,
RA   Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D.,
RA   McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I.,
RA   Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L.,
RA   Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A.,
RA   She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J.,
RA   Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 598-722.
RC   TISSUE=Skeletal muscle;
RX   PubMed=1639409; DOI=10.1016/0888-7543(92)90163-m;
RA   Otsu K., Phillips M.S., Khanna V.K., de Leon S., McLennan D.H.;
RT   "Refinement of diagnostic assays for a probable causal mutation for porcine
RT   and human malignant hyperthermia.";
RL   Genomics 13:835-837(1992).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 603-641, AND VARIANT MHS1 CYS-614.
RX   PubMed=1774074; DOI=10.1016/0888-7543(91)90084-r;
RA   Gillard E.F., Otsu K., Fujii J., Khanna V.K., de Leon S., Derdemezi J.,
RA   Britt B.A., Duff C.L., Worton R.G., MacLennan D.H.;
RT   "A substitution of cysteine for arginine 614 in the ryanodine receptor is
RT   potentially causative of human malignant hyperthermia.";
RL   Genomics 11:751-755(1991).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 603-627, AND VARIANT MHS1 CYS-614.
RX   PubMed=7751854; DOI=10.1007/bf00936884;
RA   Moroni I., Gonano E.F., Comi G.P., Tegazzin V., Prelle A., Bordoni A.,
RA   Bresolin N., Scarlato G.;
RT   "Ryanodine receptor gene point mutation and malignant hyperthermia
RT   susceptibility.";
RL   J. Neurol. 242:127-133(1995).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 4696-4974, AND SUBCELLULAR LOCATION.
RC   TISSUE=Myometrium;
RX   PubMed=7556644; DOI=10.1016/0014-5793(95)00924-x;
RA   Lynn S., Morgan J.M., Lamb H.K., Meissner G., Gillespie J.I.;
RT   "Isolation and partial cloning of ryanodine-sensitive Ca2+ release channel
RT   protein isoforms from human myometrial smooth muscle.";
RL   FEBS Lett. 372:6-12(1995).
RN   [10]
RP   TISSUE SPECIFICITY.
RX   PubMed=9607712; DOI=10.1016/s0306-4522(97)00612-x;
RA   Martin C., Chapman K.E., Seckl J.R., Ashley R.H.;
RT   "Partial cloning and differential expression of ryanodine receptor/calcium-
RT   release channel genes in human tissues including the hippocampus and
RT   cerebellum.";
RL   Neuroscience 85:205-216(1998).
RN   [11]
RP   INTERACTION WITH CALM AND S100A1, AND ACTIVITY REGULATION.
RX   PubMed=18650434; DOI=10.1074/jbc.m804432200;
RA   Wright N.T., Prosser B.L., Varney K.M., Zimmer D.B., Schneider M.F.,
RA   Weber D.J.;
RT   "S100A1 and calmodulin compete for the same binding site on ryanodine
RT   receptor.";
RL   J. Biol. Chem. 283:26676-26683(2008).
RN   [12]
RP   INVOLVEMENT IN KDS, AND VARIANT KDS GLU-33.
RX   PubMed=18765655; DOI=10.1212/01.wnl.0000324929.33780.2f;
RA   D'Arcy C.E., Bjorksten A., Yiu E.M., Bankier A., Gillies R., McLean C.A.,
RA   Shield L.K., Ryan M.M.;
RT   "King-denborough syndrome caused by a novel mutation in the ryanodine
RT   receptor gene.";
RL   Neurology 71:776-777(2008).
RN   [13]
RP   FUNCTION, PHOSPHORYLATION AT SER-2843, S-NITROSYLATION, AND IDENTIFICATION
RP   IN A COMPLEX WITH PDE4D; PKA; FKBP1A AND PROTEIN PHOSPHATASE 1.
RX   PubMed=18268335; DOI=10.1073/pnas.0711074105;
RA   Bellinger A.M., Reiken S., Dura M., Murphy P.W., Deng S.X., Landry D.W.,
RA   Nieman D., Lehnart S.E., Samaru M., LaCampagne A., Marks A.R.;
RT   "Remodeling of ryanodine receptor complex causes 'leaky' channels: a
RT   molecular mechanism for decreased exercise capacity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:2198-2202(2008).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-4864 AND SER-4867, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=18318008; DOI=10.1002/pmic.200700884;
RA   Han G., Ye M., Zhou H., Jiang X., Feng S., Jiang X., Tian R., Wan D.,
RA   Zou H., Gu J.;
RT   "Large-scale phosphoproteome analysis of human liver tissue by enrichment
RT   and fractionation of phosphopeptides with strong anion exchange
RT   chromatography.";
RL   Proteomics 8:1346-1361(2008).
RN   [15]
RP   REVIEW.
RX   PubMed=20961976; DOI=10.1101/cshperspect.a003996;
RA   Lanner J.T., Georgiou D.K., Joshi A.D., Hamilton S.L.;
RT   "Ryanodine receptors: structure, expression, molecular details, and
RT   function in calcium release.";
RL   Cold Spring Harb. Perspect. Biol. 2:E3996-E3996(2010).
RN   [16]
RP   INVOLVEMENT IN KDS, AND VARIANTS KDS ARG-2206; TRP-2452 AND PHE-2776.
RX   PubMed=21514828; DOI=10.1016/j.nmd.2011.03.006;
RA   Dowling J.J., Lillis S., Amburgey K., Zhou H., Al-Sarraj S., Buk S.J.,
RA   Wraige E., Chow G., Abbs S., Leber S., Lachlan K., Baralle D., Taylor A.,
RA   Sewry C., Muntoni F., Jungbluth H.;
RT   "King-Denborough syndrome with and without mutations in the skeletal muscle
RT   ryanodine receptor (RYR1) gene.";
RL   Neuromuscul. Disord. 21:420-427(2011).
RN   [17]
RP   INVOLVEMENT IN SAMARITAN MYOPATHY, AND VARIANT CYS-1088.
RX   PubMed=22752422; DOI=10.1007/s00401-012-1007-3;
RA   Bohm J., Leshinsky-Silver E., Vassilopoulos S., Le Gras S.,
RA   Lerman-Sagie T., Ginzberg M., Jost B., Lev D., Laporte J.;
RT   "Samaritan myopathy, an ultimately benign congenital myopathy, is caused by
RT   a RYR1 mutation.";
RL   Acta Neuropathol. 124:575-581(2012).
RN   [18]
RP   INVOLVEMENT IN KDS, AND VARIANT KDS CYS-2508.
RX   PubMed=27918309; DOI=10.1213/xaa.0000000000000421;
RA   Joseph M.R., Theroux M.C., Mooney J.J., Falitz S., Brandom B.W.,
RA   Byler D.L.;
RT   "Intraoperative Presentation of Malignant Hyperthermia (Confirmed by RYR1
RT   Gene Mutation, c.7522C>T; p.R2508C) Leads to Diagnosis of King-Denborough
RT   Syndrome in a Child With Hypotonia and Dysmorphic Features: A Case
RT   Report.";
RL   A. A. Case Rep. 8:55-57(2017).
RN   [19]
RP   VARIANTS CCD CYS-163 AND MET-403, AND VARIANTS MHS1 CYS-163 AND MET-403.
RX   PubMed=8220423; DOI=10.1038/ng0993-51;
RA   Quane K.A., Healy J.M.S., Keating K.E., Manning B.M., Couch F.J.,
RA   Palmucci L.M., Doriguzzi C., Fagerlund T.H., Berg K., Ording H.,
RA   Bendixen D., Mortier W., Linz U., Muller C.R., McCarthy T.V.;
RT   "Mutations in the ryanodine receptor gene in central core disease and
RT   malignant hyperthermia.";
RL   Nat. Genet. 5:51-55(1993).
RN   [20]
RP   VARIANT CCD SER-522.
RX   PubMed=7829078; DOI=10.1006/geno.1994.1483;
RA   Quane K.A., Keating K.E., Healy J.M.S., Manning B.M., Krivosic-Horber R.,
RA   Krivosic I., Monnier N., Lunardi J., McCarthy T.V.;
RT   "Mutation screening of the RYR1 gene in malignant hyperthermia: detection
RT   of a novel Tyr to Ser mutation in a pedigree with associated central
RT   cores.";
RL   Genomics 23:236-239(1994).
RN   [21]
RP   VARIANT MHS1 ARG-341.
RX   PubMed=8012359; DOI=10.1093/hmg/3.3.471;
RA   Quane K.A., Keating K.E., Manning B.M., Healy J.M.S., Monsieurs K.,
RA   Heffron J.J.A., Lehane M., Heytens L., Krivosic-Horber R., Adnet P.,
RA   Ellis F.R., Monnier N., Lunardi J., McCarthy T.V.;
RT   "Detection of a novel common mutation in the ryanodine receptor gene in
RT   malignant hyperthermia: implications for diagnosis and heterogeneity
RT   studies.";
RL   Hum. Mol. Genet. 3:471-476(1994).
RN   [22]
RP   VARIANT MHS1 ARG-2434.
RX   PubMed=7849712; DOI=10.1093/hmg/3.10.1855;
RA   Keating K.E., Quane K.A., Manning B.M., Lehane M., Hartung E., Censier K.,
RA   Urwyler A., Klausnitzer M., Muller C.R., Heffron J.J.A., McCarthy T.V.;
RT   "Detection of a novel RYR1 mutation in four malignant hyperthermia
RT   pedigrees.";
RL   Hum. Mol. Genet. 3:1855-1858(1994).
RN   [23]
RP   VARIANT MHS1 ARG-2434.
RX   PubMed=7881417; DOI=10.1093/hmg/3.12.2181;
RA   Phillips M.S., Khanna V.K., de Leon S., Frodis W., Britt B.A.,
RA   McLennan D.H.;
RT   "The substitution of Arg for Gly2433 in the human skeletal muscle ryanodine
RT   receptor is associated with malignant hyperthermia.";
RL   Hum. Mol. Genet. 3:2181-2186(1994).
RN   [24]
RP   VARIANT MHS1 ARG-35.
RX   PubMed=9066328; DOI=10.1097/00000542-199703000-00014;
RA   Lynch P.J., Krivosic-Horber R., Reyford H., Monnier N., Quane K.A.,
RA   Adnet P., Haudecoeur G., Krivosic I., McCarthy T.V., Lunardi J.;
RT   "Identification of heterozygous and homozygous individuals with the novel
RT   RYR1 mutation Cys35Arg in a large kindred.";
RL   Anesthesiology 86:620-626(1997).
RN   [25]
RP   VARIANT MHS1 LEU-614.
RX   PubMed=9389851; DOI=10.1093/bja/79.3.332;
RA   Quane K.A., Ording H., Keating K.E., Manning B.M., Heine R., Bendixen D.,
RA   Berg K., Krivosic-Horber R., Lehmann-Horn F., Fagerlund T.H.,
RA   McCarthy T.V.;
RT   "Detection of a novel mutation at amino acid position 614 in the ryanodine
RT   receptor in malignant hyperthermia.";
RL   Br. J. Anaesth. 79:332-337(1997).
RN   [26]
RP   VARIANT MHS1 TRP-552.
RX   PubMed=9138151; DOI=10.1136/jmg.34.4.291;
RA   Keating K.E., Giblin L., Lynch P.J., Quane K.A., Lehane M., Heffron J.J.A.,
RA   McCarthy T.V.;
RT   "Detection of a novel mutation in the ryanodine receptor gene in an Irish
RT   malignant hyperthermia pedigree: correlation of the IVCT response with the
RT   affected and unaffected haplotypes.";
RL   J. Med. Genet. 34:291-296(1997).
RN   [27]
RP   VARIANTS MHS1 CYS-2163; MET-2168 AND MET-2206, AND VARIANT CCD/MHS1
RP   HIS-2163.
RX   PubMed=9497245; DOI=10.1086/301748;
RA   Manning B.M., Quane K.A., Ording H., Urwyler A., Tegazzin V., Lehane M.,
RA   O'Halloran J., Hartung E., Giblin L.M., Lynch P.J., Vaughan P., Censier K.,
RA   Bendixen D., Comi G.P., Heytens L., Monsieurs K., Fagerlund T.H., Wolz W.,
RA   Heffron J.J.A., Mueller C.R., McCarthy T.V.;
RT   "Identification of novel mutations in the ryanodine-receptor gene (RYR1) in
RT   malignant hyperthermia: genotype-phenotype correlation.";
RL   Am. J. Hum. Genet. 62:599-609(1998).
RN   [28]
RP   VARIANTS MHS1 CYS-2458 AND HIS-2458.
RX   PubMed=9450902;
RX   DOI=10.1002/(sici)1098-1004(1998)11:1<45::aid-humu7>3.0.co;2-k;
RA   Manning B.M., Quane K.A., Lynch P.J., Urwyler A., Tegazzin V.,
RA   Krivosic-Horber R., Censier K., Comi G.P., Adnet P., Wolz W., Lunardi J.,
RA   Muller C.R., McCarthy T.V.;
RT   "Novel mutations at a CpG dinucleotide in the ryanodine receptor in
RT   malignant hyperthermia.";
RL   Hum. Mutat. 11:45-50(1998).
RN   [29]
RP   VARIANTS MHS1.
RX   PubMed=10484775; DOI=10.1093/hmg/8.11.2055;
RA   Brandt A., Schleithoff L., Jurkat-Rott K., Klingler W., Baur C.,
RA   Lehmann-Horn F.;
RT   "Screening of the ryanodine receptor gene in 105 malignant hyperthermia
RT   families: novel mutations and concordance with the in vitro contracture
RT   test.";
RL   Hum. Mol. Genet. 8:2055-2062(1999).
RN   [30]
RP   VARIANTS MHS1 LEU-2435 AND HIS-2454.
RX   PubMed=10051009;
RA   Barone V., Massa O., Intravaia E., Bracco A., Di Martino A., Tegazzin V.,
RA   Cozzolino S., Sorrentino V.;
RT   "Mutation screening of the RYR1 gene and identification of two novel
RT   mutations in Italian malignant hyperthermia families.";
RL   J. Med. Genet. 36:115-118(1999).
RN   [31]
RP   VARIANT CCD THR-4898, AND CHARACTERIZATION OF VARIANT CCD THR-4898.
RX   PubMed=10097181; DOI=10.1073/pnas.96.7.4164;
RA   Lynch P.J., Tong J., Lehane M., Mallet A., Giblin L., Heffron J.J.A.,
RA   Vaughan P., Zafra G., MacLennan D.H., McCarthy T.V.;
RT   "A mutation in the transmembrane/luminal domain of the ryanodine receptor
RT   is associated with abnormal Ca(2+) release channel function and severe
RT   central core disease.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:4164-4169(1999).
RN   [32]
RP   VARIANTS MHS1 TRP-2452 AND HIS-2454.
RX   PubMed=10823104; DOI=10.1093/oxfordjournals.bja.a013478;
RA   Chamley D., Pollock N.A., Stowell K.M., Brown R.L.;
RT   "Malignant hyperthermia in infancy and identification of novel RYR1
RT   mutation.";
RL   Br. J. Anaesth. 84:500-504(2000).
RN   [33]
RP   VARIANT MHS1 ILE-4826.
RX   PubMed=10888602; DOI=10.1093/hmg/9.10.1515;
RA   Brown R.L., Pollock A.N., Couchman K.G., Hodges M., Hutchinson D.O.,
RA   Waaka R., Lynch P., McCarthy T.V., Stowell K.M.;
RT   "A novel ryanodine receptor mutation and genotype-phenotype correlation in
RT   a large malignant hyperthermia New Zealand Maori pedigree.";
RL   Hum. Mol. Genet. 9:1515-1524(2000).
RN   [34]
RP   VARIANT MHS1 CYS-2454.
RX   PubMed=10612851;
RX   DOI=10.1002/(sici)1098-1004(200001)15:1<122::aid-humu40>3.0.co;2-a;
RA   Gencik M., Gencik A., Mortier W., Epplen J.T.;
RT   "Novel mutation in the RYR1 gene (R2454C) in a patient with malignant
RT   hyperthermia.";
RL   Hum. Mutat. 15:122-122(2000).
RN   [35]
RP   VARIANT CCD ALA-4637.
RX   PubMed=11113224; DOI=10.1212/wnl.55.11.1689;
RA   Scacheri P.C., Hoffman E.P., Fratkin J.D., Semino-Mora C., Senchak A.,
RA   Davis M.R., Laing N.G., Vedanarayanan V., Subramony S.H.;
RT   "A novel ryanodine receptor gene mutation causing both cores and rods in
RT   congenital myopathy.";
RL   Neurology 55:1689-1696(2000).
RN   [36]
RP   VARIANT MHS1 GLU-2347 DEL.
RX   PubMed=11389482; DOI=10.1086/321270;
RA   Sambuughin N., McWilliams S., de Bantel A., Sivakumar K., Nelson T.E.;
RT   "Single-amino-acid deletion in the RYR1 gene, associated with malignant
RT   hyperthermia susceptibility and unusual contraction phenotype.";
RL   Am. J. Hum. Genet. 69:204-208(2001).
RN   [37]
RP   VARIANTS MHS1 CYS-163; ARG-248; CYS-614; MET-2168; MET-2206; ILE-2214;
RP   THR-2367; ASN-2431; ARG-2434 AND HIS-2454.
RX   PubMed=11575529; DOI=10.1097/00000542-200109000-00009;
RA   Sambuughin N., Sei Y., Gallagher K.L., Wyre H.W., Madsen D., Nelson T.E.,
RA   Fletcher J.E., Rosenberg H., Muldoon S.M.;
RT   "North American malignant hyperthermia population: screening of the
RT   ryanodine receptor gene and identification of novel mutations.";
RL   Anesthesiology 95:594-599(2001).
RN   [38]
RP   VARIANTS CCD MET-2168; 4214-ARG--4216-PHE DEL; 4647-LEU-SER-4648 DEL;
RP   PRO-4793; CYS-4796; CYS-4825; PHE-4860 DEL; HIS-4861; TRP-4893; THR-4898;
RP   GLU-4899 AND GLY-4914.
RX   PubMed=11709545; DOI=10.1093/hmg/10.22.2581;
RA   Monnier N., Romero N.B., Lerale J., Landrieu P., Nivoche Y., Fardeau M.,
RA   Lunardi J.;
RT   "Familial and sporadic forms of central core disease are associated with
RT   mutations in the C-terminal domain of the skeletal muscle ryanodine
RT   receptor.";
RL   Hum. Mol. Genet. 10:2581-2592(2001).
RN   [39]
RP   VARIANTS CCD HIS-4861; ARG-4891; THR-4898; ARG-4899 AND VAL-4906,
RP   CHARACTERIZATION OF VARIANTS CCD MET-2168; HIS-4861; TRP-4893; THR-4898 AND
RP   ARG-4899, AND FUNCTION.
RX   PubMed=11741831; DOI=10.1093/hmg/10.25.2879;
RA   Tilgen N., Zorzato F., Halliger-Keller B., Muntoni F., Sewry C.,
RA   Palmucci L.M., Schneider C., Hauser E., Lehmann-Horn F., Mueller C.R.,
RA   Treves S.;
RT   "Identification of four novel mutations in the C-terminal membrane spanning
RT   domain of the ryanodine receptor 1: association with central core disease
RT   and alteration of calcium homeostasis.";
RL   Hum. Mol. Genet. 10:2879-2887(2001).
RN   [40]
RP   VARIANT MHS1 GLU-2129.
RX   PubMed=11241852; DOI=10.1002/humu.15;
RA   Rueffert H., Kraus H., Olthoff D., Deutrich C., Froster U.G.;
RT   "Identification of a novel mutation in the ryanodine receptor gene (RYR1)
RT   in patients with malignant hyperthermia.";
RL   Hum. Mutat. 17:238-238(2001).
RN   [41]
RP   VARIANT MHS1 THR-2350, AND CHARACTERIZATION OF VARIANT MHS1 THR-2350.
RX   PubMed=11525881; DOI=10.1016/s0960-8966(01)00202-4;
RA   Sambuughin N., Nelson T.E., Jankovic J., Xin C., Meissner G.,
RA   Mullakandov M., Ji J., Rosenberg H., Sivakumar K., Goldfarb L.G.;
RT   "Identification and functional characterization of a novel ryanodine
RT   receptor mutation causing malignant hyperthermia in North American and
RT   South American families.";
RL   Neuromuscul. Disord. 11:530-537(2001).
RN   [42]
RP   VARIANTS MHS1 CYS-163; ASN-166; ARG-341; HIS-401; CYS-614; GLU-2129;
RP   MET-2168; MET-2206; THR-2428; ARG-2434; HIS-2435; TRP-2452 AND HIS-2454.
RX   PubMed=12059893; DOI=10.1034/j.1399-6576.2002.460610.x;
RA   Rueffert H., Olthoff D., Deutrich C., Meinecke C.D., Froster U.G.;
RT   "Mutation screening in the ryanodine receptor 1 gene (RYR1) in patients
RT   susceptible to malignant hyperthermia who show definite IVCT results:
RT   identification of three novel mutations.";
RL   Acta Anaesthesiol. Scand. 46:692-698(2002).
RN   [43]
RP   VARIANTS MHS1 CYS-163; ARG-341; CYS-614; CYS-2454; MET-3916 AND LEU-4973.
RX   PubMed=12411788; DOI=10.1097/00000542-200211000-00007;
RA   Monnier N., Krivosic-Horber R., Payen J.-F., Kozak-Ribbens G., Nivoche Y.,
RA   Adnet P., Reyford H., Lunardi J.;
RT   "Presence of two different genetic traits in malignant hyperthermia
RT   families: implication for genetic analysis, diagnosis, and incidence of
RT   malignant hyperthermia susceptibility.";
RL   Anesthesiology 97:1067-1074(2002).
RN   [44]
RP   VARIANT CCD SER-3527.
RX   PubMed=12112081; DOI=10.1002/ana.10231;
RA   Ferreiro A., Monnier N., Romero N.B., Leroy J.-P., Boennemann C.,
RA   Haenggeli C.-A., Straub V., Voss W.D., Nivoche Y., Jungbluth H.,
RA   Lemainque A., Voit T., Lunardi J., Fardeau M., Guicheney P.;
RT   "A recessive form of central core disease, transiently presenting as multi-
RT   minicore disease, is associated with a homozygous mutation in the ryanodine
RT   receptor type 1 gene.";
RL   Ann. Neurol. 51:750-759(2002).
RN   [45]
RP   VARIANT MHS1 CYS-401.
RX   PubMed=12066726; DOI=10.1093/bja/88.4.508;
RA   Davis M., Brown R., Dickson A., Horton H., James D., Laing N., Marston R.,
RA   Norgate M., Perlman D., Pollock N., Stowell K.;
RT   "Malignant hyperthermia associated with exercise-induced rhabdomyolysis or
RT   congenital abnormalities and a novel RYR1 mutation in New Zealand and
RT   Australian pedigrees.";
RL   Br. J. Anaesth. 88:508-515(2002).
RN   [46]
RP   VARIANTS MHS1 CYS-163; CYS-401; HIS-2163; MET-2206; ILE-2280; ARG-2434;
RP   LEU-2435; CYS-2458; SER-4136; LEU-4234; TRP-4737; VAL-4942 AND LEU-4973.
RX   PubMed=12208234; DOI=10.1016/s0143-4160(02)00138-0;
RA   Galli L., Orrico A., Cozzolino S., Pietrini V., Tegazzin V., Sorrentino V.;
RT   "Mutations in the RYR1 gene in Italian patients at risk for malignant
RT   hyperthermia: evidence for a cluster of novel mutations in the C-terminal
RT   region.";
RL   Cell Calcium 32:143-151(2002).
RN   [47]
RP   VARIANT MHS1 CYS-2355.
RX   PubMed=12123492; DOI=10.1034/j.1399-0004.2002.620111.x;
RA   McWilliams S., Nelson T., Sudo R.T., Zapata-Sudo G., Batti M.,
RA   Sambuughin N.;
RT   "Novel skeletal muscle ryanodine receptor mutation in a large Brazilian
RT   family with malignant hyperthermia.";
RL   Clin. Genet. 62:80-83(2002).
RN   [48]
RP   VARIANT MHS1 VAL-4838, AND VARIANTS ALA-1832; GLU-3756 AND SER-4668.
RX   PubMed=11928716; DOI=10.1254/jjp.88.159;
RA   Oyamada H., Oguchi K., Saitoh N., Yamazawa T., Hirose K., Kawana Y.,
RA   Wakatsuki K., Oguchi K., Tagami M., Hanaoka K., Endo M., Iino M.;
RT   "Novel mutations in C-terminal channel region of the ryanodine receptor in
RT   malignant hyperthermia patients.";
RL   Jpn. J. Pharmacol. 88:159-166(2002).
RN   [49]
RP   VARIANT CCD ILE-4849.
RX   PubMed=12136074; DOI=10.1212/wnl.59.2.284;
RA   Jungbluth H., Muller C.R., Halliger-Keller B., Brockington M., Brown S.C.,
RA   Feng L., Chattopadhyay A., Mercuri E., Manzur A.Y., Ferreiro A.,
RA   Laing N.G., Davis M.R., Roper H.P., Dubowitz V., Bydder G., Sewry C.A.,
RA   Muntoni F.;
RT   "Autosomal recessive inheritance of RYR1 mutations in a congenital myopathy
RT   with cores.";
RL   Neurology 59:284-287(2002).
RN   [50]
RP   VARIANT MHS1 TRP-328, AND CHARACTERIZATION OF VARIANT MHS1 TRP-328.
RX   PubMed=12883402; DOI=10.1097/00000542-200308000-00011;
RA   Loke J.C.P., Kraev N., Sharma P., Du G., Patel L., Kraev A.,
RA   MacLennan D.H.;
RT   "Detection of a novel ryanodine receptor subtype 1 mutation (R328W) in a
RT   malignant hyperthermia family by sequencing of a leukocyte transcript.";
RL   Anesthesiology 99:297-302(2003).
RN   [51]
RP   VARIANTS CCD HIS-4861; CYS-4864; TRP-4893 AND THR-4940.
RX   PubMed=14670767; DOI=10.1136/adc.88.12.1051;
RA   Quinlivan R.M., Muller C.R., Davis M., Laing N.G., Evans G.A., Dwyer J.,
RA   Dove J., Roberts A.P., Sewry C.A.;
RT   "Central core disease: clinical, pathological, and genetic features.";
RL   Arch. Dis. Child. 88:1051-1055(2003).
RN   [52]
RP   VARIANTS CCD GLU-215; CYS-614; PRO-4650; GLN-4724 AND GLU-4899.
RX   PubMed=12937085; DOI=10.1093/brain/awg244;
RA   Romero N.B., Monnier N., Viollet L., Cortey A., Chevallay M., Leroy J.P.,
RA   Lunardi J., Fardeau M.;
RT   "Dominant and recessive central core disease associated with RYR1 mutations
RT   and fetal akinesia.";
RL   Brain 126:2341-2349(2003).
RN   [53]
RP   VARIANTS MHS1 CYS-44; CYS-533; LEU-2117; PRO-2163; MET-2168; LEU-2435 AND
RP   HIS-2454, AND VARIANT LYS-2101.
RX   PubMed=12709367; DOI=10.1373/49.5.761;
RA   Tammaro A., Bracco A., Cozzolino S., Esposito M., Di Martino A., Savoia G.,
RA   Zeuli L., Piluso G., Aurino S., Nigro V.;
RT   "Scanning for mutations of the ryanodine receptor (RYR1) gene by denaturing
RT   HPLC: detection of three novel malignant hyperthermia alleles.";
RL   Clin. Chem. 49:761-768(2003).
RN   [54]
RP   VARIANT CCD 4863-ARG--ASP-4869 DELINS TYR.
RX   PubMed=12566385; DOI=10.1093/hmg/ddg032;
RA   Zorzato F., Yamaguchi N., Xu L., Meissner G., Mueller C.R., Pouliquin P.,
RA   Muntoni F., Sewry C., Girard T., Treves S.;
RT   "Clinical and functional effects of a deletion in a COOH-terminal lumenal
RT   loop of the skeletal muscle ryanodine receptor.";
RL   Hum. Mol. Genet. 12:379-388(2003).
RN   [55]
RP   INVOLVEMENT IN MMDO.
RX   PubMed=12719381; DOI=10.1093/hmg/ddg121;
RA   Monnier N., Ferreiro A., Marty I., Labarre-Vila A., Mezin P., Lunardi J.;
RT   "A homozygous splicing mutation causing a depletion of skeletal muscle RYR1
RT   is associated with multi-minicore disease congenital myopathy with
RT   ophthalmoplegia.";
RL   Hum. Mol. Genet. 12:1171-1178(2003).
RN   [56]
RP   VARIANT CORE/ROD DISEASE ILE-4637, AND VARIANTS CCD ASP-4638; PRO-4651;
RP   CYS-4861; HIS-4861; GLN-4893; THR-4898; GLY-4914; THR-4914;
RP   4927-VAL-ILE-4928 DEL AND THR-4940.
RX   PubMed=12565913; DOI=10.1016/s0960-8966(02)00218-3;
RA   Davis M.R., Haan E., Jungbluth H., Sewry C., North K., Muntoni F.,
RA   Kuntzer T., Lamont P., Bankier A., Tomlinson P., Sanchez A., Walsh P.,
RA   Nagarajan L., Oley C., Colley A., Gedeon A., Quinlivan R., Dixon J.,
RA   James D., Mueller C.R., Laing N.G.;
RT   "Principal mutation hotspot for central core disease and related myopathies
RT   in the C-terminal transmembrane region of the RYR1 gene.";
RL   Neuromuscul. Disord. 13:151-157(2003).
RN   [57]
RP   VARIANTS MHS1 CYS-163; ARG-248; CYS-614; CYS-2163; MET-2168; MET-2206;
RP   ILE-2214; THR-2350; THR-2367; ASN-2431; ARG-2434; VAL-2437; HIS-2454 AND
RP   PRO-4824.
RX   PubMed=15448513; DOI=10.1097/00000542-200410000-00005;
RA   Sei Y., Sambuughin N.N., Davis E.J., Sachs D., Cuenca P.B., Brandom B.W.,
RA   Tautz T., Rosenberg H., Nelson T.E., Muldoon S.M.;
RT   "Malignant hyperthermia in North America: genetic screening of the three
RT   hot spots in the type I ryanodine receptor gene.";
RL   Anesthesiology 101:824-830(2004).
RN   [58]
RP   VARIANTS TRP-2676 AND SER-2787.
RX   PubMed=14732627; DOI=10.1001/archneur.61.1.106;
RA   Guis S., Figarella-Branger D., Monnier N., Bendahan D., Kozak-Ribbens G.,
RA   Mattei J.-P., Lunardi J., Cozzone P.J., Pellissier J.-F.;
RT   "Multiminicore disease in a family susceptible to malignant hyperthermia:
RT   histology, in vitro contracture tests, and genetic characterization.";
RL   Arch. Neurol. 61:106-113(2004).
RN   [59]
RP   VARIANTS CCD GLY-160; ASP-4638; PHE-4814; HIS-4861 AND MET-4938, AND
RP   VARIANTS MHS1 CYS-614; MET-2346; GLY-2348; TRP-2452; HIS-2458; PRO-4824 AND
RP   GLU-4939.
RX   PubMed=14985404; DOI=10.1136/jmg.2003.014274;
RA   Shepherd S., Ellis F., Halsall J., Hopkins P., Robinson R.;
RT   "RYR1 mutations in UK central core disease patients: more than just the C-
RT   terminal transmembrane region of the RYR1 gene.";
RL   J. Med. Genet. 41:E33-E33(2004).
RN   [60]
RP   VARIANT MHS1 SER-2342.
RX   PubMed=15221887; DOI=10.1002/mus.20068;
RA   Marchant C.L., Ellis F.R., Halsall P.J., Hopkins P.M., Robinson R.L.;
RT   "Mutation analysis of two patients with hypokalemic periodic paralysis and
RT   suspected malignant hyperthermia.";
RL   Muscle Nerve 30:114-117(2004).
RN   [61]
RP   VARIANTS MHS1 ARG-35; CYS-163; LEU-163; ARG-165; ASN-166; CYS-177; CYS-178;
RP   VAL-227; ARG-248; TRP-328; ARG-341; SER-401; HIS-401; MET-403; SER-522;
RP   TRP-552; CYS-614; LEU-614; CYS-2163; HIS-2163; MET-2168; MET-2206;
RP   ARG-2206; ASP-2344; MET-2346; THR-2350; THR-2428; ARG-2434; HIS-2435;
RP   CYS-2454; HIS-2454; CYS-2458; MET-3916; SER-4684; GLN-4737; TRP-4737;
RP   ILE-4826; VAL-4838; ILE-4849; ARG-4876; GLU-4939 AND LEU-4973, VARIANTS
RP   TRP-2676 AND SER-2787, CHARACTERIZATION OF VARIANTS MHS1 LEU-163; MET-2206;
RP   THR-2428; CYS-2454 AND HIS-2454, FUNCTION, AND ACTIVITY REGULATION.
RX   PubMed=16163667; DOI=10.1002/humu.20231;
RA   Monnier N., Kozak-Ribbens G., Krivosic-Horber R., Nivoche Y., Qi D.,
RA   Kraev N., Loke J., Sharma P., Tegazzin V., Figarella-Branger D., Romero N.,
RA   Mezin P., Bendahan D., Payen J.-F., Depret T., Maclennan D.H., Lunardi J.;
RT   "Correlations between genotype and pharmacological, histological,
RT   functional, and clinical phenotypes in malignant hyperthermia
RT   susceptibility.";
RL   Hum. Mutat. 26:413-425(2005).
RN   [62]
RP   VARIANTS MMDO TRP-109 AND LYS-2423, AND VARIANTS VAL-485 AND CYS-2060.
RX   PubMed=16380615; DOI=10.1212/01.wnl.0000188870.37076.f2;
RA   Jungbluth H., Zhou H., Hartley L., Halliger-Keller B., Messina S.,
RA   Longman C., Brockington M., Robb S.A., Straub V., Voit T., Swash M.,
RA   Ferreiro A., Bydder G., Sewry C.A., Mueller C., Muntoni F.;
RT   "Minicore myopathy with ophthalmoplegia caused by mutations in the
RT   ryanodine receptor type 1 gene.";
RL   Neurology 65:1930-1935(2005).
RN   [63]
RP   VARIANT CCD VAL-4846.
RX   PubMed=17204054; DOI=10.1111/j.1399-0004.2006.00725.x;
RA   Gambelli S., Malandrini A., Berti G., Gaudiano C., Zicari E., Brunori P.,
RA   Perticoni G., Orrico A., Galli L., Sorrentino V., Lunardi J., Federico A.,
RA   Dotti M.T.;
RT   "Inheritance of a novel RYR1 mutation in a family with myotonic dystrophy
RT   type 1.";
RL   Clin. Genet. 71:93-94(2007).
RN   [64]
RP   VARIANTS CCD GLN-4558; VAL-4846; ILE-4849; HIS-4861; CYS-4861; VAL-4897 AND
RP   THR-4914.
RX   PubMed=17226826; DOI=10.1002/mus.20715;
RA   Kossugue P.M., Paim J.F., Navarro M.M., Silva H.C., Pavanello R.C.M.,
RA   Gurgel-Giannetti J., Zatz M., Vainzof M.;
RT   "Central core disease due to recessive mutations in RYR1 gene: is it more
RT   common than described?";
RL   Muscle Nerve 35:670-674(2007).
RN   [65]
RP   VARIANT CCD MET-4882.
RX   PubMed=18312400; DOI=10.1111/j.1468-1331.2008.02094.x;
RA   von der Hagen M., Kress W., Hahn G., Brocke K.S., Mitzscherling P.,
RA   Huebner A., Muller-Reible C., Stoltenburg-Didinger G., Kaindl A.M.;
RT   "Novel RYR1 missense mutation causes core rod myopathy.";
RL   Eur. J. Neurol. 15:E31-E32(2008).
RN   [66]
RP   VARIANTS CCD VAL-13; SER-1704; PRO-2421; LYS-2423; HIS-3539; GLN-3772;
RP   GLN-4558; MET-4842 AND ILE-4849.
RX   PubMed=18253926; DOI=10.1002/humu.20696;
RA   Monnier N., Marty I., Faure J., Castiglioni C., Desnuelle C., Sacconi S.,
RA   Estournet B., Ferreiro A., Romero N., Laquerriere A., Lazaro L.,
RA   Martin J.-J., Morava E., Rossi A., Van der Kooi A., de Visser M.,
RA   Verschuuren C., Lunardi J.;
RT   "Null mutations causing depletion of the type 1 ryanodine receptor (RYR1)
RT   are commonly associated with recessive structural congenital myopathies
RT   with cores.";
RL   Hum. Mutat. 29:670-678(2008).
RN   [67]
RP   VARIANTS MHS1 ARG-13; LYS-226; LEU-367; HIS-530; TYR-544; CYS-1043;
RP   HIS-2336; LYS-2404; GLY-2730; LYS-2880; PRO-3217; LYS-3290; TRP-3772;
RP   ARG-3806; VAL-4838; ARG-4876 AND THR-4938, AND VARIANTS GLY-1342; GLY-1352;
RP   LEU-1787; ALA-1832; CYS-2060; VAL-2321; VAL-2550; TRP-2676; SER-2787;
RP   GLN-3583; GLU-3756 AND LEU-4501.
RX   PubMed=19191329; DOI=10.1002/humu.20878;
RA   Levano S., Vukcevic M., Singer M., Matter A., Treves S., Urwyler A.,
RA   Girard T.;
RT   "Increasing the number of diagnostic mutations in malignant hyperthermia.";
RL   Hum. Mutat. 30:590-598(2009).
RN   [68]
RP   VARIANT MHS1 CYS-2508.
RX   PubMed=19685112; DOI=10.1007/s00540-009-0746-3;
RA   Migita T., Mukaida K., Hamada H., Yasuda T., Haraki T., Nishino I.,
RA   Murakami N., Kawamoto M.;
RT   "Functional analysis of ryanodine receptor type 1 p.R2508C mutation in exon
RT   47.";
RL   J. Anesth. 23:341-346(2009).
RN   [69]
RP   VARIANTS MHS1 ASN-382; LYS-1058 AND ARG-1393, VARIANT CCD GLY-2508, AND
RP   VARIANT HIS-1679.
RX   PubMed=20142353; DOI=10.1213/ane.0b013e3181cbd815;
RA   Vukcevic M., Broman M., Islander G., Bodelsson M., Ranklev-Twetman E.,
RA   Muller C.R., Treves S.;
RT   "Functional properties of RYR1 mutations identified in Swedish patients
RT   with malignant hyperthermia and central core disease.";
RL   Anesth. Analg. 111:185-190(2010).
RN   [70]
RP   VARIANTS MMDO THR-402; LEU-2035; LYS-3326 AND GLY-3402.
RX   PubMed=20583297; DOI=10.1002/humu.21278;
RA   Clarke N.F., Waddell L.B., Cooper S.T., Perry M., Smith R.L.L.,
RA   Kornberg A.J., Muntoni F., Lillis S., Straub V., Bushby K., Guglieri M.,
RA   King M.D., Farrell M.A., Marty I., Lunardi J., Monnier N., North K.N.;
RT   "Recessive mutations in RYR1 are a common cause of congenital fiber type
RT   disproportion.";
RL   Hum. Mutat. 31:E1544-E1550(2010).
RN   [71]
RP   VARIANTS MHS1 ASN-1056; HIS-1127; ARG-1467; VAL-1571; GLN-2013; GLY-2400;
RP   GLY-2593; GLN-3410; TYR-3501 AND CYS-3933, AND VARIANTS LYS-899; CYS-2060;
RP   CYS-2248; TYR-2976 AND GLN-3360.
RX   PubMed=20681998; DOI=10.1111/j.1399-0004.2010.01493.x;
RA   Tammaro A., Di Martino A., Bracco A., Cozzolino S., Savoia G., Andria B.,
RA   Cannavo A., Spagnuolo M., Piluso G., Aurino S., Nigro V.;
RT   "Novel missense mutations and unexpected multiple changes of RYR1 gene in
RT   75 malignant hyperthermia families.";
RL   Clin. Genet. 79:438-447(2011).
RN   [72]
RP   VARIANTS CCD GLY-160; GLN-2204; HIS-3366; CYS-3933 AND ASP-4743, AND
RP   VARIANTS LEU-1787; CYS-2060 AND ALA-4493.
RX   PubMed=21674524; DOI=10.1002/mus.22009;
RA   Duarte S.T., Oliveira J., Santos R., Pereira P., Barroso C., Conceicao I.,
RA   Evangelista T.;
RT   "Dominant and recessive RYR1 mutations in adults with core lesions and mild
RT   muscle symptoms.";
RL   Muscle Nerve 44:102-108(2011).
RN   [73]
RP   VARIANTS MHS1 HIS-1056; MET-2627 AND LEU-4234.
RX   PubMed=24013571; DOI=10.1097/aln.0b013e3182a8a998;
RA   Kim J.H., Jarvik G.P., Browning B.L., Rajagopalan R., Gordon A.S.,
RA   Rieder M.J., Robertson P.D., Nickerson D.A., Fisher N.A., Hopkins P.M.;
RT   "Exome sequencing reveals novel rare variants in the ryanodine receptor and
RT   calcium channel genes in malignant hyperthermia families.";
RL   Anesthesiology 119:1054-1065(2013).
RN   [74]
RP   VARIANTS MHS1 ALA-40; CYS-163; ARG-248; ARG-341; PRO-487; ALA-518; CYS-614;
RP   HIS-1043; HIS-2163; MET-2206; HIS-2248; HIS-2351; MET-2354; LEU-2358;
RP   GLN-2383; ARG-2434; HIS-2454; ARG-3711; VAL-4178; ARG-4230; GLU-4837;
RP   HIS-4861 AND GLY-4906, VARIANTS CCD TRP-975; MET-2168 AND GLY-3238, AND
RP   VARIANTS MET-974; LEU-1109; ARG-1393; LEU-1787; CYS-2060 AND VAL-2321.
RX   PubMed=23558838; DOI=10.1213/ane.0b013e31828a71ff;
RA   Brandom B.W., Bina S., Wong C.A., Wallace T., Visoiu M., Isackson P.J.,
RA   Vladutiu G.D., Sambuughin N., Muldoon S.M.;
RT   "Ryanodine receptor type 1 gene variants in the malignant hyperthermia-
RT   susceptible population of the United States.";
RL   Anesth. Analg. 116:1078-1086(2013).
RN   [75]
RP   VARIANTS CCD HIS-4861; ALA-4897 AND THR-4898.
RX   PubMed=24561095; DOI=10.1016/j.neulet.2014.02.015;
RA   Gu M., Zhang S., Hu J., Yuan Y., Wang Z., Da Y., Wu S.;
RT   "Novel RYR1 missense mutations in six Chinese patients with central core
RT   disease.";
RL   Neurosci. Lett. 566:32-35(2014).
RN   [76]
RP   CHARACTERIZATION OF VARIANT CCD GLY-2508, CHARACTERIZATION OF VARIANT MHS1
RP   HIS-2508, AND MUTAGENESIS OF ARG-2508.
RX   PubMed=26381711; DOI=10.1213/ane.0000000000000886;
RA   Miyoshi H., Yasuda T., Otsuki S., Kondo T., Haraki T., Mukaida K.,
RA   Nakamura R., Hamada H., Kawamoto M.;
RT   "Several ryanodine receptor type 1 gene mutations of p.Arg2508 are
RT   potential sources of malignant hyperthermia.";
RL   Anesth. Analg. 121:994-1000(2015).
RN   [77]
RP   CHARACTERIZATION OF VARIANTS MHS1 ARG-35; CYS-163; LEU-163; ARG-248;
RP   ARG-341; CYS-401; HIS-401; SER-522; CYS-614 AND LEU-614, AND MUTAGENESIS OF
RP   TYR-522.
RX   PubMed=26115329; DOI=10.1371/journal.pone.0130606;
RA   Murayama T., Kurebayashi N., Yamazawa T., Oyamada H., Suzuki J.,
RA   Kanemaru K., Oguchi K., Iino M., Sakurai T.;
RT   "Divergent activity profiles of type 1 ryanodine receptor channels carrying
RT   malignant hyperthermia and central core disease mutations in the amino-
RT   terminal Region.";
RL   PLoS ONE 10:E0130606-E0130606(2015).
RN   [78]
RP   CHARACTERIZATION OF VARIANTS MHS1 CYS-2163; HIS-2163; MET-2168; MET-2206;
RP   THR-2350; ARG-2434; HIS-2435; CYS-2454; HIS-2454; CYS-2458; HIS-2458 AND
RP   HIS-2508, CHARACTERIZATION OF VARIANT CCD CYS-2508, AND CHARACTERIZATION OF
RP   VARIANT ALA-2375 AND HIS-2508.
RX   PubMed=27586648; DOI=10.1002/humu.23072;
RA   Murayama T., Kurebayashi N., Ogawa H., Yamazawa T., Oyamada H., Suzuki J.,
RA   Kanemaru K., Oguchi K., Iino M., Sakurai T.;
RT   "Genotype-phenotype correlations of malignant hyperthermia and central core
RT   disease mutations in the central region of the RYR1 channel.";
RL   Hum. Mutat. 37:1231-1241(2016).
RN   [79]
RP   VARIANT MHS1 TRP-4737, AND CHARACTERIZATION OF VARIANT MHS1 TRP-4737.
RX   PubMed=26631338; DOI=10.1016/j.nmd.2015.11.001;
RA   Johannsen S., Treves S., Mueller C.R., Moegele S., Schneiderbanger D.,
RA   Roewer N., Schuster F.;
RT   "Functional characterization of the RYR1 mutation p.Arg4737Trp associated
RT   with susceptibility to malignant hyperthermia.";
RL   Neuromuscul. Disord. 26:21-25(2016).
RN   [80]
RP   VARIANT ARG-705.
RX   PubMed=27616680; DOI=10.1002/pd.4925;
RA   Casey J., Flood K., Ennis S., Doyle E., Farrell M., Lynch S.A.;
RT   "Intra-familial variability associated with recessive RYR1 mutation
RT   diagnosed prenatally by exome sequencing.";
RL   Prenat. Diagn. 36:1020-1026(2016).
RN   [81]
RP   VARIANTS CCD PRO-2963 AND ASP-4806.
RX   PubMed=27234031; DOI=10.1111/cge.12810;
RA   Fattahi Z., Kalhor Z., Fadaee M., Vazehan R., Parsimehr E., Abolhassani A.,
RA   Beheshtian M., Zamani G., Nafissi S., Nilipour Y., Akbari M.R., Kahrizi K.,
RA   Kariminejad A., Najmabadi H.;
RT   "Improved diagnostic yield of neuromuscular disorders applying clinical
RT   exome sequencing in patients arising from a consanguineous population.";
RL   Clin. Genet. 91:386-402(2017).
CC   -!- FUNCTION: Calcium channel that mediates the release of Ca(2+) from the
CC       sarcoplasmic reticulum into the cytoplasm and thereby plays a key role
CC       in triggering muscle contraction following depolarization of T-tubules
CC       (PubMed:11741831, PubMed:16163667). Repeated very high-level exercise
CC       increases the open probability of the channel and leads to Ca(2+)
CC       leaking into the cytoplasm (PubMed:18268335). Can also mediate the
CC       release of Ca(2+) from intracellular stores in neurons, and may thereby
CC       promote prolonged Ca(2+) signaling in the brain. Required for normal
CC       embryonic development of muscle fibers and skeletal muscle. Required
CC       for normal heart morphogenesis, skin development and ossification
CC       during embryogenesis (By similarity). {ECO:0000250|UniProtKB:E9PZQ0,
CC       ECO:0000269|PubMed:18268335, ECO:0000305|PubMed:11741831,
CC       ECO:0000305|PubMed:16163667}.
CC   -!- ACTIVITY REGULATION: Channel activity is modulated by the alkaloid
CC       ryanodine that binds to the open Ca-release channel with high affinity.
CC       At low concentrations, ryanodine maintains the channel in an open
CC       conformation. High ryanodine concentrations inhibit channel activity
CC       (By similarity). Channel activity is regulated by calmodulin (CALM)
CC       (PubMed:18650434). The calcium release is activated by increased
CC       cytoplasmic calcium levels, by nitric oxyde (NO), caffeine and ATP
CC       (PubMed:18268335, PubMed:16163667). Channel activity is inhibited by
CC       magnesium ions, possibly by competition for calcium binding sites (By
CC       similarity). {ECO:0000250|UniProtKB:P11716,
CC       ECO:0000269|PubMed:16163667, ECO:0000269|PubMed:18268335,
CC       ECO:0000269|PubMed:18650434}.
CC   -!- SUBUNIT: Homotetramer. Can also form heterotetramers with RYR2 (By
CC       similarity). Identified in a complex composed of RYR1, PDE4D, PKA,
CC       FKBP1A and protein phosphatase 1 (PP1) (PubMed:18268335). Repeated very
CC       high-level exercise decreases interaction with PDE4D and protein
CC       phosphatase 1 (PP1) (PubMed:18268335). Interacts with CALM; CALM with
CC       bound calcium inhibits the RYR1 channel activity (PubMed:18650434).
CC       Interacts with S100A1 (PubMed:18650434). Interacts with FKBP1A; this
CC       stabilizes the closed conformation of the channel. Interacts with
CC       CACNA1S; interaction with CACNA1S is important for activation of the
CC       RYR1 channel. Interacts with CACNB1. Interacts with TRDN and ASPH;
CC       these interactions stimulate RYR1 channel activity. Interacts with
CC       SELENON (By similarity). Interacts with scorpion calcins (AC P0DPT1; AC
CC       P0DM30; AC A0A1L4BJ42; AC P59868; AC P60254; AC B8QG00; AC L0GBR1; AC
CC       P60252; AC P60253) (By similarity). {ECO:0000250|UniProtKB:E9PZQ0,
CC       ECO:0000250|UniProtKB:P11716, ECO:0000269|PubMed:18268335,
CC       ECO:0000269|PubMed:18650434}.
CC   -!- SUBCELLULAR LOCATION: Sarcoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:7556644}; Multi-pass membrane protein
CC       {ECO:0000305}. Sarcoplasmic reticulum {ECO:0000250|UniProtKB:P11716}.
CC       Note=The number of predicted transmembrane domains varies between
CC       orthologs, but the 3D-structures show the presence of six transmembrane
CC       regions. Both N-terminus and C-terminus are cytoplasmic.
CC       {ECO:0000250|UniProtKB:P11716}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC         Comment=Experimental confirmation may be lacking for some isoforms.;
CC       Name=1;
CC         IsoId=P21817-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P21817-2; Sequence=VSP_005951;
CC       Name=3;
CC         IsoId=P21817-3; Sequence=VSP_005952;
CC   -!- TISSUE SPECIFICITY: Skeletal muscle and brain (cerebellum and
CC       hippocampus). {ECO:0000269|PubMed:9607712}.
CC   -!- DOMAIN: The calcium release channel activity resides in the C-terminal
CC       region while the remaining part of the protein constitutes the 'foot'
CC       structure spanning the junctional gap between the sarcoplasmic
CC       reticulum (SR) and the T-tubule. Pore opening is mediated via the
CC       cytoplasmic calcium-binding domains that mediate a small rotation of
CC       the channel-forming transmembrane regions that then leads to channel
CC       opening. {ECO:0000250|UniProtKB:P11716}.
CC   -!- PTM: Channel activity is modulated by phosphorylation. Phosphorylation
CC       at Ser-2843 may increase channel activity. Repeated very high-level
CC       exercise increases phosphorylation at Ser-2843.
CC       {ECO:0000269|PubMed:18268335}.
CC   -!- PTM: Activated by reversible S-nitrosylation (By similarity). Repeated
CC       very high-level exercise increases S-nitrosylation (PubMed:18268335).
CC       {ECO:0000250|UniProtKB:P11716, ECO:0000269|PubMed:18268335}.
CC   -!- DISEASE: Malignant hyperthermia 1 (MHS1) [MIM:145600]: Autosomal
CC       dominant pharmacogenetic disorder of skeletal muscle and is one of the
CC       main causes of death due to anesthesia. In susceptible people, an MH
CC       episode can be triggered by all commonly used inhalational anesthetics
CC       such as halothane and by depolarizing muscle relaxants such as
CC       succinylcholine. The clinical features of the myopathy are
CC       hyperthermia, accelerated muscle metabolism, contractures, metabolic
CC       acidosis, tachycardia and death, if not treated with the postsynaptic
CC       muscle relaxant, dantrolene. Susceptibility to MH can be determined
CC       with the 'in vitro' contracture test (IVCT): observing the magnitude of
CC       contractures induced in strips of muscle tissue by caffeine alone and
CC       halothane alone. Patients with normal response are MH normal (MHN),
CC       those with abnormal response to caffeine alone or halothane alone are
CC       MH equivocal (MHE(C) and MHE(H) respectively).
CC       {ECO:0000269|PubMed:10051009, ECO:0000269|PubMed:10484775,
CC       ECO:0000269|PubMed:10612851, ECO:0000269|PubMed:10823104,
CC       ECO:0000269|PubMed:10888602, ECO:0000269|PubMed:11241852,
CC       ECO:0000269|PubMed:11389482, ECO:0000269|PubMed:11525881,
CC       ECO:0000269|PubMed:11575529, ECO:0000269|PubMed:11928716,
CC       ECO:0000269|PubMed:12059893, ECO:0000269|PubMed:12066726,
CC       ECO:0000269|PubMed:12123492, ECO:0000269|PubMed:12208234,
CC       ECO:0000269|PubMed:12411788, ECO:0000269|PubMed:12709367,
CC       ECO:0000269|PubMed:12883402, ECO:0000269|PubMed:1354642,
CC       ECO:0000269|PubMed:14732627, ECO:0000269|PubMed:14985404,
CC       ECO:0000269|PubMed:15221887, ECO:0000269|PubMed:15448513,
CC       ECO:0000269|PubMed:16163667, ECO:0000269|PubMed:1774074,
CC       ECO:0000269|PubMed:19191329, ECO:0000269|PubMed:19685112,
CC       ECO:0000269|PubMed:20142353, ECO:0000269|PubMed:20681998,
CC       ECO:0000269|PubMed:23558838, ECO:0000269|PubMed:24013571,
CC       ECO:0000269|PubMed:26115329, ECO:0000269|PubMed:26381711,
CC       ECO:0000269|PubMed:26631338, ECO:0000269|PubMed:27586648,
CC       ECO:0000269|PubMed:7751854, ECO:0000269|PubMed:7849712,
CC       ECO:0000269|PubMed:7881417, ECO:0000269|PubMed:8012359,
CC       ECO:0000269|PubMed:8220423, ECO:0000269|PubMed:9066328,
CC       ECO:0000269|PubMed:9138151, ECO:0000269|PubMed:9389851,
CC       ECO:0000269|PubMed:9450902, ECO:0000269|PubMed:9497245}. Note=Disease
CC       susceptibility is associated with variants affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Central core disease of muscle (CCD) [MIM:117000]: Autosomal
CC       dominant congenital myopathy, but a severe autosomal recessive form
CC       also exists. Both clinical and histological variability is observed.
CC       Affected individuals typically display hypotonia and proximal muscle
CC       weakness in infancy, leading to the delay of motor milestones. The
CC       clinical course of the disorder is usually slow or nonprogressive in
CC       adulthood, and the severity of the symptoms may vary from normal to
CC       significant muscle weakness. Microscopic examination of CCD-affected
CC       skeletal muscle reveals a predominance of type I fibers containing
CC       amorphous-looking areas (cores) that do not stain with oxidative and
CC       phosphorylase histochemical techniques. {ECO:0000269|PubMed:10097181,
CC       ECO:0000269|PubMed:11113224, ECO:0000269|PubMed:11709545,
CC       ECO:0000269|PubMed:11741831, ECO:0000269|PubMed:12112081,
CC       ECO:0000269|PubMed:12136074, ECO:0000269|PubMed:12565913,
CC       ECO:0000269|PubMed:12566385, ECO:0000269|PubMed:12937085,
CC       ECO:0000269|PubMed:14670767, ECO:0000269|PubMed:14985404,
CC       ECO:0000269|PubMed:17204054, ECO:0000269|PubMed:17226826,
CC       ECO:0000269|PubMed:18253926, ECO:0000269|PubMed:18312400,
CC       ECO:0000269|PubMed:20142353, ECO:0000269|PubMed:21674524,
CC       ECO:0000269|PubMed:23558838, ECO:0000269|PubMed:24561095,
CC       ECO:0000269|PubMed:26381711, ECO:0000269|PubMed:27234031,
CC       ECO:0000269|PubMed:27586648, ECO:0000269|PubMed:7829078,
CC       ECO:0000269|PubMed:8220422, ECO:0000269|PubMed:8220423,
CC       ECO:0000269|PubMed:9497245}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Multiminicore disease with external ophthalmoplegia (MMDO)
CC       [MIM:255320]: Clinically heterogeneous neuromuscular disorder. General
CC       features include neonatal hypotonia, delayed motor development, and
CC       generalized muscle weakness and amyotrophy, which may progress slowly
CC       or remain stable. Muscle biopsy shows multiple, poorly circumscribed,
CC       short areas of sarcomere disorganization and mitochondria depletion
CC       (areas termed minicores) in most muscle fibers. Typically, no
CC       dystrophic signs, such as muscle fiber necrosis or regeneration or
CC       significant endomysial fibrosis, are present in multiminicore disease.
CC       {ECO:0000269|PubMed:12719381, ECO:0000269|PubMed:16380615,
CC       ECO:0000269|PubMed:20583297}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Note=Defects in RYR1 may be a cause of Samaritan myopathy, a
CC       congenital myopathy with benign course. Patients display severe
CC       hypotonia and respiratory distress at birth. Unlike other congenital
CC       myopathies, the health status constantly improves and patients are
CC       minimally affected at adulthood.
CC   -!- DISEASE: King-Denborough syndrome (KDS) [MIM:619542]: An autosomal
CC       dominant disorder characterized by the triad of dysmorphic features,
CC       congenital myopathy, and susceptibility to malignant hyperthermia.
CC       Variable expressivity has been reported in several cases.
CC       {ECO:0000269|PubMed:18765655, ECO:0000269|PubMed:21514828,
CC       ECO:0000269|PubMed:27918309}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Coexpression of normal and mutant Thr-4898 RYR1 in a 1:1
CC       ratio produces RYR1 channels with normal halothane and caffeine
CC       sensitivities, but maximal levels of Ca(2+) release are reduced by 67%.
CC       Binding of [3H]ryanodine indicates that the heterozygous channel is
CC       activated by Ca(2+) concentrations 4-fold lower than normal. Single-
CC       cell analysis of cotransfected cells shows a significantly increased
CC       resting cytoplasmic Ca(2+) level and a significantly reduced luminal
CC       Ca(2+) level. These data indicated a leaky channel, possibly caused by
CC       a reduction in the Ca(2+) concentration required for channel
CC       activation. Comparison with 2 other coexpressed mutant/normal channels
CC       suggests that the Thr-4898 mutation produces one of the most abnormal
CC       RYR1 channels that has been investigated, and this level of abnormality
CC       is reflected in the severe and penetrant phenotype of affected CCD
CC       individuals. {ECO:0000269|PubMed:10097181}.
CC   -!- SIMILARITY: Belongs to the ryanodine receptor (TC 1.A.3.1) family. RYR1
CC       subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Ryanodine receptor entry;
CC       URL="https://en.wikipedia.org/wiki/Ryanodine_receptor";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=RYR1 entry;
CC       URL="https://databases.lovd.nl/shared/genes//RYR1";
CC   -!- WEB RESOURCE: Name=Leiden Muscular Dystrophy pages Ryanodine receptor 1
CC       (skeletal) (RYR1); Note=Leiden Open Variation Database (LOVD);
CC       URL="https://databases.lovd.nl/shared/genes/RYR1";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; J05200; AAA60294.1; -; mRNA.
DR   EMBL; U48508; AAC51191.1; -; Genomic_DNA.
DR   EMBL; U48449; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48450; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48451; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48452; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48453; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48454; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48455; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48456; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48457; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48458; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48459; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48460; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48461; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48462; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48463; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48464; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48465; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48466; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48467; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48468; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48469; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48470; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48471; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48472; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48473; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48474; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48475; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48476; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48477; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48478; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48479; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48480; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48481; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48482; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48483; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48484; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48485; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48486; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48487; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48488; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48489; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48490; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48491; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48492; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48493; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48494; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48495; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48496; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48497; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48498; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48499; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48500; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48501; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48502; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48503; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48504; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48505; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48506; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; U48507; AAC51191.1; JOINED; Genomic_DNA.
DR   EMBL; AC067969; AAF66076.1; -; Genomic_DNA.
DR   EMBL; AC005933; AAC71651.1; -; Genomic_DNA.
DR   EMBL; AC011469; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M91455; AAA60295.1; -; Genomic_DNA.
DR   EMBL; S78717; AAB21245.2; -; Genomic_DNA.
DR   EMBL; S77392; AAB34356.1; -; Genomic_DNA.
DR   CCDS; CCDS33011.1; -. [P21817-1]
DR   CCDS; CCDS42563.1; -. [P21817-2]
DR   PIR; A35041; A35041.
DR   RefSeq; NP_000531.2; NM_000540.2. [P21817-1]
DR   RefSeq; NP_001036188.1; NM_001042723.1. [P21817-2]
DR   PDB; 6UHI; X-ray; 2.88 A; A=849-962.
DR   PDB; 6UHS; X-ray; 2.46 A; A=849-962.
DR   PDBsum; 6UHI; -.
DR   PDBsum; 6UHS; -.
DR   SMR; P21817; -.
DR   BioGRID; 112173; 26.
DR   ComplexPortal; CPX-3135; Ryanodine 1 complex.
DR   DIP; DIP-29708N; -.
DR   ELM; P21817; -.
DR   IntAct; P21817; 14.
DR   MINT; P21817; -.
DR   STRING; 9606.ENSP00000352608; -.
DR   BindingDB; P21817; -.
DR   ChEMBL; CHEMBL1846; -.
DR   DrugBank; DB00201; Caffeine.
DR   DrugBank; DB11093; Calcium citrate.
DR   DrugBank; DB11348; Calcium Phosphate.
DR   DrugBank; DB14481; Calcium phosphate dihydrate.
DR   DrugBank; DB01219; Dantrolene.
DR   DrugBank; DB04786; Suramin.
DR   DrugBank; DB09085; Tetracaine.
DR   DrugCentral; P21817; -.
DR   TCDB; 1.A.3.1.2; the ryanodine-inositol 1,4,5-triphosphate receptor ca(2+) channel (rir-cac) family.
DR   CarbonylDB; P21817; -.
DR   GlyGen; P21817; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; P21817; -.
DR   PhosphoSitePlus; P21817; -.
DR   SwissPalm; P21817; -.
DR   BioMuta; RYR1; -.
DR   DMDM; 108935904; -.
DR   EPD; P21817; -.
DR   jPOST; P21817; -.
DR   MassIVE; P21817; -.
DR   PaxDb; P21817; -.
DR   PeptideAtlas; P21817; -.
DR   ProteomicsDB; 53930; -. [P21817-1]
DR   ProteomicsDB; 53931; -. [P21817-2]
DR   ProteomicsDB; 53932; -. [P21817-3]
DR   Antibodypedia; 44914; 178 antibodies from 25 providers.
DR   DNASU; 6261; -.
DR   Ensembl; ENST00000355481.8; ENSP00000347667.3; ENSG00000196218.14. [P21817-2]
DR   Ensembl; ENST00000359596.8; ENSP00000352608.2; ENSG00000196218.14. [P21817-1]
DR   GeneID; 6261; -.
DR   KEGG; hsa:6261; -.
DR   MANE-Select; ENST00000359596.8; ENSP00000352608.2; NM_000540.3; NP_000531.2.
DR   UCSC; uc002oit.4; human. [P21817-1]
DR   AGR; HGNC:10483; -.
DR   CTD; 6261; -.
DR   DisGeNET; 6261; -.
DR   GeneCards; RYR1; -.
DR   GeneReviews; RYR1; -.
DR   HGNC; HGNC:10483; RYR1.
DR   HPA; ENSG00000196218; Tissue enriched (skeletal).
DR   MalaCards; RYR1; -.
DR   MIM; 117000; phenotype.
DR   MIM; 145600; phenotype.
DR   MIM; 180901; gene.
DR   MIM; 255320; phenotype.
DR   MIM; 619542; phenotype.
DR   neXtProt; NX_P21817; -.
DR   OpenTargets; ENSG00000196218; -.
DR   Orphanet; 169189; Autosomal dominant centronuclear myopathy.
DR   Orphanet; 169186; Autosomal recessive centronuclear myopathy.
DR   Orphanet; 324581; Benign Samaritan congenital myopathy.
DR   Orphanet; 597; Central core disease.
DR   Orphanet; 98905; Congenital multicore myopathy with external ophthalmoplegia.
DR   Orphanet; 424107; Congenital myopathy with myasthenic-like onset.
DR   Orphanet; 466650; Exercise-induced malignant hyperthermia.
DR   Orphanet; 99741; King-Denborough syndrome.
DR   Orphanet; 33108; Lethal multiple pterygium syndrome.
DR   Orphanet; 423; Malignant hyperthermia of anesthesia.
DR   Orphanet; 178145; Moderate multiminicore disease with hand involvement.
DR   PharmGKB; PA34896; -.
DR   VEuPathDB; HostDB:ENSG00000196218; -.
DR   eggNOG; KOG2243; Eukaryota.
DR   GeneTree; ENSGT00940000155288; -.
DR   HOGENOM; CLU_000040_2_0_1; -.
DR   InParanoid; P21817; -.
DR   OMA; VMMDDLQ; -.
DR   OrthoDB; 3144451at2759; -.
DR   PhylomeDB; P21817; -.
DR   TreeFam; TF315244; -.
DR   PathwayCommons; P21817; -.
DR   Reactome; R-HSA-2672351; Stimuli-sensing channels.
DR   Reactome; R-HSA-5578775; Ion homeostasis.
DR   SignaLink; P21817; -.
DR   SIGNOR; P21817; -.
DR   BioGRID-ORCS; 6261; 18 hits in 1159 CRISPR screens.
DR   ChiTaRS; RYR1; human.
DR   GeneWiki; RYR1; -.
DR   GenomeRNAi; 6261; -.
DR   Pharos; P21817; Tclin.
DR   PRO; PR:P21817; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; P21817; protein.
DR   Bgee; ENSG00000196218; Expressed in gluteal muscle and 139 other tissues.
DR   ExpressionAtlas; P21817; baseline and differential.
DR   Genevisible; P21817; HS.
DR   GO; GO:0034704; C:calcium channel complex; IBA:GO_Central.
DR   GO; GO:0005938; C:cell cortex; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0030659; C:cytoplasmic vesicle membrane; IBA:GO_Central.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0031674; C:I band; IDA:UniProtKB.
DR   GO; GO:0014701; C:junctional sarcoplasmic reticulum membrane; TAS:BHF-UCL.
DR   GO; GO:0031090; C:organelle membrane; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:1990425; C:ryanodine receptor complex; ISS:UniProtKB.
DR   GO; GO:0042383; C:sarcolemma; IBA:GO_Central.
DR   GO; GO:0016529; C:sarcoplasmic reticulum; ISS:BHF-UCL.
DR   GO; GO:0033017; C:sarcoplasmic reticulum membrane; IDA:UniProtKB.
DR   GO; GO:0005790; C:smooth endoplasmic reticulum; IBA:GO_Central.
DR   GO; GO:0014802; C:terminal cisterna; ISS:UniProtKB.
DR   GO; GO:0030018; C:Z disc; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; ISS:UniProtKB.
DR   GO; GO:0005262; F:calcium channel activity; ISS:UniProtKB.
DR   GO; GO:0005509; F:calcium ion binding; ISS:UniProtKB.
DR   GO; GO:0048763; F:calcium-induced calcium release activity; IMP:UniProtKB.
DR   GO; GO:0015278; F:calcium-release channel activity; TAS:ProtInc.
DR   GO; GO:0005516; F:calmodulin binding; ISS:BHF-UCL.
DR   GO; GO:0005219; F:ryanodine-sensitive calcium-release channel activity; IDA:CACAO.
DR   GO; GO:0005245; F:voltage-gated calcium channel activity; ISS:UniProtKB.
DR   GO; GO:0006816; P:calcium ion transport; ISS:BHF-UCL.
DR   GO; GO:0071313; P:cellular response to caffeine; IMP:UniProtKB.
DR   GO; GO:0071277; P:cellular response to calcium ion; ISS:UniProtKB.
DR   GO; GO:0006936; P:muscle contraction; ISS:UniProtKB.
DR   GO; GO:0043931; P:ossification involved in bone maturation; ISS:UniProtKB.
DR   GO; GO:0003151; P:outflow tract morphogenesis; ISS:UniProtKB.
DR   GO; GO:0051289; P:protein homotetramerization; ISS:UniProtKB.
DR   GO; GO:0051480; P:regulation of cytosolic calcium ion concentration; ISS:BHF-UCL.
DR   GO; GO:0051209; P:release of sequestered calcium ion into cytosol; IMP:UniProtKB.
DR   GO; GO:0014808; P:release of sequestered calcium ion into cytosol by sarcoplasmic reticulum; ISS:UniProtKB.
DR   GO; GO:0031000; P:response to caffeine; ISS:BHF-UCL.
DR   GO; GO:0001666; P:response to hypoxia; IDA:BHF-UCL.
DR   GO; GO:0048741; P:skeletal muscle fiber development; ISS:UniProtKB.
DR   GO; GO:0043588; P:skin development; ISS:UniProtKB.
DR   CDD; cd12877; SPRY1_RyR; 1.
DR   CDD; cd12878; SPRY2_RyR; 1.
DR   CDD; cd12879; SPRY3_RyR; 1.
DR   Gene3D; 1.10.287.70; -; 1.
DR   Gene3D; 1.10.490.160; -; 2.
DR   Gene3D; 2.60.120.920; -; 3.
DR   Gene3D; 2.80.10.50; -; 2.
DR   Gene3D; 6.20.350.10; -; 1.
DR   Gene3D; 1.25.10.30; IP3 receptor type 1 binding core, RIH domain; 1.
DR   InterPro; IPR001870; B30.2/SPRY.
DR   InterPro; IPR043136; B30.2/SPRY_sf.
DR   InterPro; IPR013320; ConA-like_dom_sf.
DR   InterPro; IPR011992; EF-hand-dom_pair.
DR   InterPro; IPR014821; Ins145_P3_rcpt.
DR   InterPro; IPR005821; Ion_trans_dom.
DR   InterPro; IPR036300; MIR_dom_sf.
DR   InterPro; IPR016093; MIR_motif.
DR   InterPro; IPR013662; RIH_assoc-dom.
DR   InterPro; IPR000699; RIH_dom.
DR   InterPro; IPR013333; Ryan_recept.
DR   InterPro; IPR015925; Ryanodine_IP3_receptor.
DR   InterPro; IPR003032; Ryanodine_rcpt.
DR   InterPro; IPR009460; Ryanrecept_TM4-6.
DR   InterPro; IPR035910; RyR/IP3R_RIH_dom_sf.
DR   InterPro; IPR035761; SPRY1_RyR.
DR   InterPro; IPR035764; SPRY2_RyR.
DR   InterPro; IPR035762; SPRY3_RyR.
DR   InterPro; IPR003877; SPRY_dom.
DR   PANTHER; PTHR46399; B30.2/SPRY DOMAIN-CONTAINING PROTEIN; 1.
DR   PANTHER; PTHR46399:SF10; RYANODINE RECEPTOR 1; 1.
DR   Pfam; PF08709; Ins145_P3_rec; 1.
DR   Pfam; PF00520; Ion_trans; 1.
DR   Pfam; PF02815; MIR; 1.
DR   Pfam; PF08454; RIH_assoc; 1.
DR   Pfam; PF06459; RR_TM4-6; 1.
DR   Pfam; PF01365; RYDR_ITPR; 2.
DR   Pfam; PF02026; RyR; 4.
DR   Pfam; PF00622; SPRY; 3.
DR   PRINTS; PR00795; RYANODINER.
DR   SMART; SM00472; MIR; 4.
DR   SMART; SM00449; SPRY; 3.
DR   SUPFAM; SSF49899; Concanavalin A-like lectins/glucanases; 2.
DR   SUPFAM; SSF47473; EF-hand; 1.
DR   SUPFAM; SSF100909; IP3 receptor type 1 binding core, domain 2; 2.
DR   SUPFAM; SSF82109; MIR domain; 2.
DR   PROSITE; PS50188; B302_SPRY; 3.
DR   PROSITE; PS50919; MIR; 5.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Calcium; Calcium channel;
KW   Calcium transport; Calmodulin-binding; Developmental protein;
KW   Direct protein sequencing; Disease variant; Ion channel; Ion transport;
KW   Ligand-gated ion channel; Membrane; Metal-binding; Nucleotide-binding;
KW   Phosphoprotein; Receptor; Reference proteome; Repeat; S-nitrosylation;
KW   Sarcoplasmic reticulum; Transmembrane; Transmembrane helix; Transport.
FT   CHAIN           1..5038
FT                   /note="Ryanodine receptor 1"
FT                   /id="PRO_0000219358"
FT   TOPO_DOM        1..4559
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   TRANSMEM        4560..4580
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   TOPO_DOM        4581..4641
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   TRANSMEM        4642..4662
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   TOPO_DOM        4663..4780
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   TRANSMEM        4781..4803
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   TOPO_DOM        4804
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   TRANSMEM        4805..4821
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   TOPO_DOM        4822..4836
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   TRANSMEM        4837..4857
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   TOPO_DOM        4858..4880
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   INTRAMEM        4881..4900
FT                   /note="Pore-forming"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   TOPO_DOM        4901..4920
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   TRANSMEM        4921..4941
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   TOPO_DOM        4942..5038
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   DOMAIN          97..152
FT                   /note="MIR 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00131"
FT   DOMAIN          159..204
FT                   /note="MIR 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00131"
FT   DOMAIN          210..264
FT                   /note="MIR 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00131"
FT   DOMAIN          270..327
FT                   /note="MIR 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00131"
FT   DOMAIN          335..392
FT                   /note="MIR 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00131"
FT   DOMAIN          581..797
FT                   /note="B30.2/SPRY 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00548"
FT   REPEAT          841..954
FT                   /note="1"
FT   REPEAT          955..1068
FT                   /note="2"
FT   DOMAIN          1013..1208
FT                   /note="B30.2/SPRY 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00548"
FT   REPEAT          1344..1359
FT                   /note="3; truncated"
FT   DOMAIN          1356..1570
FT                   /note="B30.2/SPRY 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00548"
FT   REPEAT          1372..1387
FT                   /note="4; truncated"
FT   REPEAT          2726..2845
FT                   /note="5"
FT   REPEAT          2846..2959
FT                   /note="6"
FT   DOMAIN          4074..4102
FT                   /note="EF-hand"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   REGION          669..680
FT                   /note="Interaction with FKBP1A"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   REGION          841..2959
FT                   /note="6 X approximate repeats"
FT   REGION          1307..1385
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1867..1923
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2391..2412
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2828..2858
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          3478..3501
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          3614..3643
FT                   /note="Interaction with CALM"
FT                   /evidence="ECO:0000269|PubMed:18650434"
FT   REGION          4251..4280
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          4382..4538
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          4589..4621
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           4895..4901
FT                   /note="Selectivity filter"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   COMPBIAS        1370..1385
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1870..1919
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2828..2843
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        4485..4501
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        4502..4519
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        4520..4534
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         3892
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   BINDING         3966
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   BINDING         4210..4214
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   BINDING         4717
FT                   /ligand="caffeine"
FT                   /ligand_id="ChEBI:CHEBI:27732"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   BINDING         4955..4960
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   BINDING         4980..4986
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   BINDING         5002
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   MOD_RES         1337
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:F1LMY4"
FT   MOD_RES         2345
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:F1LMY4"
FT   MOD_RES         2843
FT                   /note="Phosphoserine; by PKA and PKG"
FT                   /evidence="ECO:0000250|UniProtKB:E9PZQ0"
FT   MOD_RES         3635
FT                   /note="S-nitrosocysteine"
FT                   /evidence="ECO:0000250|UniProtKB:P11716"
FT   MOD_RES         4467
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:F1LMY4"
FT   MOD_RES         4471
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:F1LMY4"
FT   MOD_RES         4864
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:18318008"
FT   MOD_RES         4867
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18318008"
FT   VAR_SEQ         3481..3485
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:2298749"
FT                   /id="VSP_005951"
FT   VAR_SEQ         3865..3869
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_005952"
FT   VARIANT         13
FT                   /note="L -> R (in MHS1; dbSNP:rs193922744)"
FT                   /evidence="ECO:0000269|PubMed:19191329"
FT                   /id="VAR_058560"
FT   VARIANT         13
FT                   /note="L -> V (in CCD; autosomal recessive form)"
FT                   /evidence="ECO:0000269|PubMed:18253926"
FT                   /id="VAR_045694"
FT   VARIANT         33
FT                   /note="K -> E (in KDS; dbSNP:rs193922746)"
FT                   /evidence="ECO:0000269|PubMed:18765655"
FT                   /id="VAR_086256"
FT   VARIANT         35
FT                   /note="C -> R (in MHS1; increases calcium-induced calcium
FT                   release activity; dbSNP:rs193922747)"
FT                   /evidence="ECO:0000269|PubMed:16163667,
FT                   ECO:0000269|PubMed:26115329, ECO:0000269|PubMed:9066328"
FT                   /id="VAR_005589"
FT   VARIANT         40
FT                   /note="G -> A (in MHS1; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:23558838"
FT                   /id="VAR_071721"
FT   VARIANT         44
FT                   /note="R -> C (in CCD and MHS1; dbSNP:rs193922748)"
FT                   /evidence="ECO:0000269|PubMed:12709367"
FT                   /id="VAR_045695"
FT   VARIANT         109
FT                   /note="R -> W (in MMDO; dbSNP:rs118192173)"
FT                   /evidence="ECO:0000269|PubMed:16380615"
FT                   /id="VAR_032910"
FT   VARIANT         160
FT                   /note="E -> G (in CCD; dbSNP:rs193922752)"
FT                   /evidence="ECO:0000269|PubMed:14985404,
FT                   ECO:0000269|PubMed:21674524"
FT                   /id="VAR_045696"
FT   VARIANT         163
FT                   /note="R -> C (in CCD and MHS1; 2-3% of the cases;
FT                   increases calcium-induced calcium release activity;
FT                   dbSNP:rs118192161)"
FT                   /evidence="ECO:0000269|PubMed:11575529,
FT                   ECO:0000269|PubMed:12059893, ECO:0000269|PubMed:12208234,
FT                   ECO:0000269|PubMed:12411788, ECO:0000269|PubMed:15448513,
FT                   ECO:0000269|PubMed:23558838, ECO:0000269|PubMed:26115329,
FT                   ECO:0000269|PubMed:8220423, ECO:0000305|PubMed:16163667"
FT                   /id="VAR_005590"
FT   VARIANT         163
FT                   /note="R -> L (in MHS1; induces an increase sensitivity to
FT                   caffeine; increases calcium-induced calcium release
FT                   activity; dbSNP:rs193922753)"
FT                   /evidence="ECO:0000269|PubMed:16163667,
FT                   ECO:0000269|PubMed:26115329"
FT                   /id="VAR_045697"
FT   VARIANT         165
FT                   /note="G -> R (in MHS1; dbSNP:rs193922754)"
FT                   /evidence="ECO:0000269|PubMed:16163667"
FT                   /id="VAR_045698"
FT   VARIANT         166
FT                   /note="D -> N (in MHS1; dbSNP:rs193922755)"
FT                   /evidence="ECO:0000269|PubMed:12059893,
FT                   ECO:0000269|PubMed:16163667"
FT                   /id="VAR_045699"
FT   VARIANT         177
FT                   /note="R -> C (in MHS1; dbSNP:rs193922757)"
FT                   /evidence="ECO:0000269|PubMed:16163667"
FT                   /id="VAR_045700"
FT   VARIANT         178
FT                   /note="Y -> C (in MHS1)"
FT                   /evidence="ECO:0000269|PubMed:16163667"
FT                   /id="VAR_045701"
FT   VARIANT         215
FT                   /note="G -> E (in CCD; autosomal recessive form;
FT                   dbSNP:rs118192115)"
FT                   /evidence="ECO:0000269|PubMed:12937085"
FT                   /id="VAR_045702"
FT   VARIANT         226
FT                   /note="M -> K (in MHS1; dbSNP:rs112596687)"
FT                   /evidence="ECO:0000269|PubMed:19191329"
FT                   /id="VAR_058561"
FT   VARIANT         227
FT                   /note="D -> V (in MHS1; dbSNP:rs193922760)"
FT                   /evidence="ECO:0000269|PubMed:16163667"
FT                   /id="VAR_045703"
FT   VARIANT         248
FT                   /note="G -> R (in MHS1; unknown pathological significance;
FT                   increases calcium-induced calcium release activity;
FT                   dbSNP:rs1801086)"
FT                   /evidence="ECO:0000269|PubMed:11575529,
FT                   ECO:0000269|PubMed:1354642, ECO:0000269|PubMed:15448513,
FT                   ECO:0000269|PubMed:16163667, ECO:0000269|PubMed:23558838,
FT                   ECO:0000269|PubMed:26115329"
FT                   /id="VAR_005591"
FT   VARIANT         291
FT                   /note="A -> T (in dbSNP:rs2229140)"
FT                   /id="VAR_051890"
FT   VARIANT         328
FT                   /note="R -> W (in MHS1; has increased sensitivity to both
FT                   caffeine and halothane; dbSNP:rs193922762)"
FT                   /evidence="ECO:0000269|PubMed:12883402,
FT                   ECO:0000269|PubMed:16163667"
FT                   /id="VAR_045704"
FT   VARIANT         341
FT                   /note="G -> R (in MHS1; 10% of the cases; increases
FT                   calcium-induced calcium release activity;
FT                   dbSNP:rs121918592)"
FT                   /evidence="ECO:0000269|PubMed:12059893,
FT                   ECO:0000269|PubMed:12411788, ECO:0000269|PubMed:16163667,
FT                   ECO:0000269|PubMed:23558838, ECO:0000269|PubMed:26115329,
FT                   ECO:0000269|PubMed:8012359"
FT                   /id="VAR_005592"
FT   VARIANT         367
FT                   /note="R -> L (in MHS1; dbSNP:rs113332073)"
FT                   /evidence="ECO:0000269|PubMed:19191329"
FT                   /id="VAR_058562"
FT   VARIANT         382
FT                   /note="H -> N (in MHS1)"
FT                   /evidence="ECO:0000269|PubMed:20142353"
FT                   /id="VAR_068510"
FT   VARIANT         401
FT                   /note="R -> C (in MHS1; increases calcium-induced calcium
FT                   release activity; dbSNP:rs193922764)"
FT                   /evidence="ECO:0000269|PubMed:12066726,
FT                   ECO:0000269|PubMed:12208234, ECO:0000269|PubMed:26115329"
FT                   /id="VAR_045705"
FT   VARIANT         401
FT                   /note="R -> H (in MHS1; increases calcium-induced calcium
FT                   release activity; dbSNP:rs193922766)"
FT                   /evidence="ECO:0000269|PubMed:12059893,
FT                   ECO:0000269|PubMed:16163667, ECO:0000269|PubMed:26115329"
FT                   /id="VAR_045706"
FT   VARIANT         401
FT                   /note="R -> S (in MHS1)"
FT                   /evidence="ECO:0000269|PubMed:16163667"
FT                   /id="VAR_045707"
FT   VARIANT         402
FT                   /note="M -> T (in MMDO; dbSNP:rs118192117)"
FT                   /evidence="ECO:0000269|PubMed:20583297"
FT                   /id="VAR_063846"
FT   VARIANT         403
FT                   /note="I -> M (in CCD and MHS1; dbSNP:rs118192116)"
FT                   /evidence="ECO:0000269|PubMed:16163667,
FT                   ECO:0000269|PubMed:8220423"
FT                   /id="VAR_005593"
FT   VARIANT         471
FT                   /note="R -> C (in dbSNP:rs1376393998)"
FT                   /evidence="ECO:0000269|PubMed:1354642"
FT                   /id="VAR_005594"
FT   VARIANT         485
FT                   /note="M -> V (in dbSNP:rs147723844)"
FT                   /evidence="ECO:0000269|PubMed:16380615"
FT                   /id="VAR_032911"
FT   VARIANT         487
FT                   /note="L -> P (in MHS1; unknown pathological significance;
FT                   dbSNP:rs1008860336)"
FT                   /evidence="ECO:0000269|PubMed:23558838"
FT                   /id="VAR_071722"
FT   VARIANT         518
FT                   /note="V -> A (in MHS1; unknown pathological significance;
FT                   dbSNP:rs1195513704)"
FT                   /evidence="ECO:0000269|PubMed:23558838"
FT                   /id="VAR_071723"
FT   VARIANT         522
FT                   /note="Y -> S (in CCD and MHS1; increases calcium-induced
FT                   calcium release activity; dbSNP:rs118192162)"
FT                   /evidence="ECO:0000269|PubMed:16163667,
FT                   ECO:0000269|PubMed:26115329, ECO:0000269|PubMed:7829078"
FT                   /id="VAR_005595"
FT   VARIANT         530
FT                   /note="R -> H (in MHS1; dbSNP:rs111888148)"
FT                   /evidence="ECO:0000269|PubMed:19191329"
FT                   /id="VAR_058563"
FT   VARIANT         533
FT                   /note="R -> C (in MHS1; dbSNP:rs193922768)"
FT                   /evidence="ECO:0000269|PubMed:12709367"
FT                   /id="VAR_045708"
FT   VARIANT         533
FT                   /note="R -> H (in MHS1; dbSNP:rs144336148)"
FT                   /id="VAR_008971"
FT   VARIANT         544
FT                   /note="D -> Y (in MHS1; dbSNP:rs113812662)"
FT                   /evidence="ECO:0000269|PubMed:19191329"
FT                   /id="VAR_058564"
FT   VARIANT         552
FT                   /note="R -> W (in MHS1; dbSNP:rs193922770)"
FT                   /evidence="ECO:0000269|PubMed:16163667,
FT                   ECO:0000269|PubMed:9138151"
FT                   /id="VAR_005596"
FT   VARIANT         614
FT                   /note="R -> C (in CCD and MHS1; 3-5% of the cases;
FT                   increases calcium-induced calcium release activity;
FT                   dbSNP:rs118192172)"
FT                   /evidence="ECO:0000269|PubMed:11575529,
FT                   ECO:0000269|PubMed:12059893, ECO:0000269|PubMed:12411788,
FT                   ECO:0000269|PubMed:12937085, ECO:0000269|PubMed:14985404,
FT                   ECO:0000269|PubMed:15448513, ECO:0000269|PubMed:16163667,
FT                   ECO:0000269|PubMed:1774074, ECO:0000269|PubMed:23558838,
FT                   ECO:0000269|PubMed:26115329, ECO:0000269|PubMed:7751854"
FT                   /id="VAR_005597"
FT   VARIANT         614
FT                   /note="R -> L (in MHS1; increases calcium-induced calcium
FT                   release activity; dbSNP:rs193922772)"
FT                   /evidence="ECO:0000269|PubMed:16163667,
FT                   ECO:0000269|PubMed:26115329, ECO:0000269|PubMed:9389851"
FT                   /id="VAR_005598"
FT   VARIANT         705
FT                   /note="G -> R (probable disease-associated variant found in
FT                   primary myopathy causing fetal akinesia and pregnancy loss;
FT                   dbSNP:rs565825739)"
FT                   /evidence="ECO:0000269|PubMed:27616680"
FT                   /id="VAR_078775"
FT   VARIANT         899
FT                   /note="N -> K (in dbSNP:rs201401814)"
FT                   /evidence="ECO:0000269|PubMed:20681998"
FT                   /id="VAR_071724"
FT   VARIANT         974
FT                   /note="V -> M (in dbSNP:rs748676912)"
FT                   /evidence="ECO:0000269|PubMed:23558838"
FT                   /id="VAR_071725"
FT   VARIANT         975
FT                   /note="R -> W (in CCD; unknown pathological significance;
FT                   dbSNP:rs371278145)"
FT                   /evidence="ECO:0000269|PubMed:23558838"
FT                   /id="VAR_071726"
FT   VARIANT         1043
FT                   /note="R -> C (in MHS1; dbSNP:rs111272095)"
FT                   /evidence="ECO:0000269|PubMed:19191329"
FT                   /id="VAR_058565"
FT   VARIANT         1043
FT                   /note="R -> H (in MHS1; unknown pathological significance;
FT                   dbSNP:rs374776563)"
FT                   /evidence="ECO:0000269|PubMed:23558838"
FT                   /id="VAR_071727"
FT   VARIANT         1056
FT                   /note="D -> H (in MHS1)"
FT                   /evidence="ECO:0000269|PubMed:24013571"
FT                   /id="VAR_071728"
FT   VARIANT         1056
FT                   /note="D -> N (in MHS1)"
FT                   /evidence="ECO:0000269|PubMed:20681998"
FT                   /id="VAR_071729"
FT   VARIANT         1058
FT                   /note="E -> K (in MHS1; dbSNP:rs1968107192)"
FT                   /evidence="ECO:0000269|PubMed:20142353"
FT                   /id="VAR_068511"
FT   VARIANT         1088
FT                   /note="Y -> C (probable disease-associated variant found in
FT                   a family with Samaritan myopathy)"
FT                   /evidence="ECO:0000269|PubMed:22752422"
FT                   /id="VAR_068512"
FT   VARIANT         1109
FT                   /note="R -> K (in dbSNP:rs35719391)"
FT                   /id="VAR_032912"
FT   VARIANT         1109
FT                   /note="R -> L"
FT                   /evidence="ECO:0000269|PubMed:23558838"
FT                   /id="VAR_071730"
FT   VARIANT         1127
FT                   /note="R -> H (in MHS1; dbSNP:rs545579559)"
FT                   /evidence="ECO:0000269|PubMed:20681998"
FT                   /id="VAR_071731"
FT   VARIANT         1342
FT                   /note="S -> G (in dbSNP:rs34694816)"
FT                   /evidence="ECO:0000269|PubMed:19191329"
FT                   /id="VAR_032913"
FT   VARIANT         1352
FT                   /note="A -> G (may be associated with susceptibility to
FT                   malignant hyperthermia; dbSNP:rs112105381)"
FT                   /evidence="ECO:0000269|PubMed:19191329"
FT                   /id="VAR_058566"
FT   VARIANT         1393
FT                   /note="K -> R (in MHS1; unknown pathological significance;
FT                   dbSNP:rs137933390)"
FT                   /evidence="ECO:0000269|PubMed:20142353,
FT                   ECO:0000269|PubMed:23558838"
FT                   /id="VAR_068513"
FT   VARIANT         1467
FT                   /note="K -> R (in MHS1; dbSNP:rs145573319)"
FT                   /evidence="ECO:0000269|PubMed:20681998"
FT                   /id="VAR_071732"
FT   VARIANT         1489
FT                   /note="S -> N (in dbSNP:rs34404839)"
FT                   /id="VAR_032914"
FT   VARIANT         1571
FT                   /note="I -> V (in MHS1; dbSNP:rs146429605)"
FT                   /evidence="ECO:0000269|PubMed:20681998"
FT                   /id="VAR_071733"
FT   VARIANT         1679
FT                   /note="R -> H (may be associated with susceptibility to
FT                   malignant hyperthermia; dbSNP:rs146504767)"
FT                   /evidence="ECO:0000269|PubMed:20142353"
FT                   /id="VAR_068514"
FT   VARIANT         1704
FT                   /note="G -> S (in CCD; autosomal recessive form;
FT                   dbSNP:rs193922779)"
FT                   /evidence="ECO:0000269|PubMed:18253926"
FT                   /id="VAR_045709"
FT   VARIANT         1787
FT                   /note="P -> L (may be associated with susceptibility to
FT                   malignant hyperthermia; dbSNP:rs34934920)"
FT                   /evidence="ECO:0000269|PubMed:1354642,
FT                   ECO:0000269|PubMed:19191329, ECO:0000269|PubMed:21674524,
FT                   ECO:0000269|PubMed:23558838"
FT                   /id="VAR_005599"
FT   VARIANT         1832
FT                   /note="G -> A (in dbSNP:rs193922784)"
FT                   /evidence="ECO:0000269|PubMed:11928716,
FT                   ECO:0000269|PubMed:19191329, ECO:0000269|PubMed:8661021"
FT                   /id="VAR_045710"
FT   VARIANT         2013
FT                   /note="K -> Q (in MHS1)"
FT                   /evidence="ECO:0000269|PubMed:20681998"
FT                   /id="VAR_071734"
FT   VARIANT         2035
FT                   /note="H -> L (in MMDO; dbSNP:rs367543056)"
FT                   /evidence="ECO:0000269|PubMed:20583297"
FT                   /id="VAR_063847"
FT   VARIANT         2060
FT                   /note="G -> C (may be associated with susceptibility to
FT                   malignant hyperthermia; dbSNP:rs35364374)"
FT                   /evidence="ECO:0000269|PubMed:1354642,
FT                   ECO:0000269|PubMed:16380615, ECO:0000269|PubMed:19191329,
FT                   ECO:0000269|PubMed:20681998, ECO:0000269|PubMed:21674524,
FT                   ECO:0000269|PubMed:23558838"
FT                   /id="VAR_005600"
FT   VARIANT         2101
FT                   /note="M -> K (in dbSNP:rs746818096)"
FT                   /evidence="ECO:0000269|PubMed:12709367"
FT                   /id="VAR_045711"
FT   VARIANT         2117
FT                   /note="V -> L (in MHS1; dbSNP:rs193922788)"
FT                   /evidence="ECO:0000269|PubMed:12709367"
FT                   /id="VAR_045712"
FT   VARIANT         2129
FT                   /note="D -> E (in MHS1; dbSNP:rs117886618)"
FT                   /evidence="ECO:0000269|PubMed:11241852,
FT                   ECO:0000269|PubMed:12059893"
FT                   /id="VAR_045713"
FT   VARIANT         2163
FT                   /note="R -> C (in MHS1; increases calcium-induced calcium
FT                   release activity; dbSNP:rs118192175)"
FT                   /evidence="ECO:0000269|PubMed:15448513,
FT                   ECO:0000269|PubMed:16163667, ECO:0000269|PubMed:9497245,
FT                   ECO:0000305|PubMed:27586648"
FT                   /id="VAR_005601"
FT   VARIANT         2163
FT                   /note="R -> H (in CCD and MHS1; increases calcium-induced
FT                   calcium release activity; dbSNP:rs118192163)"
FT                   /evidence="ECO:0000269|PubMed:12208234,
FT                   ECO:0000269|PubMed:16163667, ECO:0000269|PubMed:23558838,
FT                   ECO:0000269|PubMed:9497245, ECO:0000305|PubMed:27586648"
FT                   /id="VAR_005602"
FT   VARIANT         2163
FT                   /note="R -> P (in MHS1; dbSNP:rs118192163)"
FT                   /evidence="ECO:0000269|PubMed:12709367"
FT                   /id="VAR_008972"
FT   VARIANT         2168
FT                   /note="V -> M (in CCD and MHS1; no difference in the
FT                   thapsigargin-sensitive calcium stores of cells carrying
FT                   this mutation and the wild-type; increases calcium-induced
FT                   calcium release activity; dbSNP:rs118192176)"
FT                   /evidence="ECO:0000269|PubMed:11575529,
FT                   ECO:0000269|PubMed:11709545, ECO:0000269|PubMed:11741831,
FT                   ECO:0000269|PubMed:12059893, ECO:0000269|PubMed:12709367,
FT                   ECO:0000269|PubMed:15448513, ECO:0000269|PubMed:16163667,
FT                   ECO:0000269|PubMed:23558838, ECO:0000269|PubMed:9497245,
FT                   ECO:0000305|PubMed:27586648"
FT                   /id="VAR_005603"
FT   VARIANT         2204
FT                   /note="H -> Q (in CCD; dbSNP:rs141646642)"
FT                   /evidence="ECO:0000269|PubMed:21674524"
FT                   /id="VAR_068515"
FT   VARIANT         2206
FT                   /note="T -> M (in MHS1; induces an increase sensitivity to
FT                   caffeine; dbSNP:rs118192177)"
FT                   /evidence="ECO:0000269|PubMed:11575529,
FT                   ECO:0000269|PubMed:12059893, ECO:0000269|PubMed:12208234,
FT                   ECO:0000269|PubMed:15448513, ECO:0000269|PubMed:23558838,
FT                   ECO:0000269|PubMed:9497245, ECO:0000305|PubMed:16163667,
FT                   ECO:0000305|PubMed:27586648"
FT                   /id="VAR_005604"
FT   VARIANT         2206
FT                   /note="T -> R (in MHS1 and KDS; dbSNP:rs118192177)"
FT                   /evidence="ECO:0000269|PubMed:16163667,
FT                   ECO:0000269|PubMed:21514828"
FT                   /id="VAR_008973"
FT   VARIANT         2214
FT                   /note="V -> I (in MHS1; dbSNP:rs193922795)"
FT                   /evidence="ECO:0000269|PubMed:11575529,
FT                   ECO:0000269|PubMed:15448513"
FT                   /id="VAR_045714"
FT   VARIANT         2248
FT                   /note="R -> C (in dbSNP:rs763352221)"
FT                   /evidence="ECO:0000269|PubMed:20681998"
FT                   /id="VAR_071735"
FT   VARIANT         2248
FT                   /note="R -> H (in MHS1; unknown pathological significance;
FT                   dbSNP:rs140152019)"
FT                   /evidence="ECO:0000269|PubMed:23558838"
FT                   /id="VAR_071736"
FT   VARIANT         2280
FT                   /note="V -> I (in MHS1; dbSNP:rs193922797)"
FT                   /evidence="ECO:0000269|PubMed:12208234"
FT                   /id="VAR_045715"
FT   VARIANT         2321
FT                   /note="I -> V (in dbSNP:rs34390345)"
FT                   /evidence="ECO:0000269|PubMed:19191329,
FT                   ECO:0000269|PubMed:23558838"
FT                   /id="VAR_058567"
FT   VARIANT         2336
FT                   /note="R -> H (in MHS1; dbSNP:rs112563513)"
FT                   /evidence="ECO:0000269|PubMed:19191329"
FT                   /id="VAR_058568"
FT   VARIANT         2342
FT                   /note="N -> S (in MHS1; dbSNP:rs147213895)"
FT                   /evidence="ECO:0000269|PubMed:15221887"
FT                   /id="VAR_045716"
FT   VARIANT         2344
FT                   /note="E -> D (in MHS1; unknown pathological significance;
FT                   dbSNP:rs193922798)"
FT                   /evidence="ECO:0000269|PubMed:16163667"
FT                   /id="VAR_045717"
FT   VARIANT         2346
FT                   /note="V -> M (in MHS1; dbSNP:rs193922799)"
FT                   /evidence="ECO:0000269|PubMed:14985404,
FT                   ECO:0000269|PubMed:16163667"
FT                   /id="VAR_045718"
FT   VARIANT         2347
FT                   /note="Missing (in MHS1)"
FT                   /evidence="ECO:0000269|PubMed:11389482"
FT                   /id="VAR_045719"
FT   VARIANT         2348
FT                   /note="E -> G (in MHS1; dbSNP:rs193922801)"
FT                   /evidence="ECO:0000269|PubMed:14985404"
FT                   /id="VAR_045720"
FT   VARIANT         2350
FT                   /note="A -> T (in MHS1; reveals an altered calcium
FT                   dependence and increased caffeine sensitivity; increases
FT                   calcium-induced calcium release activity;
FT                   dbSNP:rs193922802)"
FT                   /evidence="ECO:0000269|PubMed:11525881,
FT                   ECO:0000269|PubMed:15448513, ECO:0000269|PubMed:16163667,
FT                   ECO:0000305|PubMed:27586648"
FT                   /id="VAR_045721"
FT   VARIANT         2351
FT                   /note="N -> H (in MHS1; unknown pathological significance;
FT                   dbSNP:rs376176332)"
FT                   /evidence="ECO:0000269|PubMed:23558838"
FT                   /id="VAR_071738"
FT   VARIANT         2354
FT                   /note="V -> M (in MHS1; unknown pathological significance;
FT                   dbSNP:rs746971794)"
FT                   /evidence="ECO:0000269|PubMed:23558838"
FT                   /id="VAR_071739"
FT   VARIANT         2355
FT                   /note="R -> C (in MHS1)"
FT                   /evidence="ECO:0000269|PubMed:12123492"
FT                   /id="VAR_045722"
FT   VARIANT         2358
FT                   /note="I -> L (in MHS1; unknown pathological significance;
FT                   dbSNP:rs759306349)"
FT                   /evidence="ECO:0000269|PubMed:23558838"
FT                   /id="VAR_071740"
FT   VARIANT         2367
FT                   /note="A -> T (in MHS1; dbSNP:rs146306934)"
FT                   /evidence="ECO:0000269|PubMed:11575529,
FT                   ECO:0000269|PubMed:15448513"
FT                   /id="VAR_045723"
FT   VARIANT         2375
FT                   /note="G -> A (increases calcium-induced calcium release
FT                   activity; dbSNP:rs193922807)"
FT                   /evidence="ECO:0000305|PubMed:27586648"
FT                   /id="VAR_077682"
FT   VARIANT         2383
FT                   /note="A -> Q (in MHS1; requires 2 nucleotide
FT                   substitutions; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:23558838"
FT                   /id="VAR_071741"
FT   VARIANT         2400
FT                   /note="D -> G (in MHS1; dbSNP:rs976108591)"
FT                   /evidence="ECO:0000269|PubMed:20681998"
FT                   /id="VAR_071742"
FT   VARIANT         2404
FT                   /note="E -> K (in MHS1; dbSNP:rs111364296)"
FT                   /evidence="ECO:0000269|PubMed:19191329"
FT                   /id="VAR_058569"
FT   VARIANT         2421
FT                   /note="A -> P (in CCD; autosomal recessive form;
FT                   dbSNP:rs193922808)"
FT                   /evidence="ECO:0000269|PubMed:18253926"
FT                   /id="VAR_045724"
FT   VARIANT         2423
FT                   /note="M -> K (in MMDO and CCD; autosomal recessive form;
FT                   dbSNP:rs118192174)"
FT                   /evidence="ECO:0000269|PubMed:16380615,
FT                   ECO:0000269|PubMed:18253926"
FT                   /id="VAR_032915"
FT   VARIANT         2428
FT                   /note="A -> T (in MHS1; induces an increase sensitivity to
FT                   caffeine; dbSNP:rs193922809)"
FT                   /evidence="ECO:0000269|PubMed:12059893,
FT                   ECO:0000305|PubMed:16163667"
FT                   /id="VAR_045725"
FT   VARIANT         2431
FT                   /note="D -> N (in MHS1; dbSNP:rs193922810)"
FT                   /evidence="ECO:0000269|PubMed:11575529,
FT                   ECO:0000269|PubMed:15448513"
FT                   /id="VAR_045726"
FT   VARIANT         2434
FT                   /note="G -> R (in MHS1; increases calcium-induced calcium
FT                   release activity; dbSNP:rs121918593)"
FT                   /evidence="ECO:0000269|PubMed:11575529,
FT                   ECO:0000269|PubMed:12059893, ECO:0000269|PubMed:12208234,
FT                   ECO:0000269|PubMed:15448513, ECO:0000269|PubMed:16163667,
FT                   ECO:0000269|PubMed:23558838, ECO:0000269|PubMed:7849712,
FT                   ECO:0000269|PubMed:7881417, ECO:0000305|PubMed:27586648"
FT                   /id="VAR_005605"
FT   VARIANT         2435
FT                   /note="R -> H (in CCD and MHS1; increases calcium-induced
FT                   calcium release activity; dbSNP:rs28933396)"
FT                   /evidence="ECO:0000269|PubMed:12059893,
FT                   ECO:0000269|PubMed:16163667, ECO:0000269|PubMed:8220422,
FT                   ECO:0000305|PubMed:27586648"
FT                   /id="VAR_005606"
FT   VARIANT         2435
FT                   /note="R -> L (in MHS1; dbSNP:rs28933396)"
FT                   /evidence="ECO:0000269|PubMed:10051009,
FT                   ECO:0000269|PubMed:12208234, ECO:0000269|PubMed:12709367"
FT                   /id="VAR_008974"
FT   VARIANT         2437
FT                   /note="A -> V (in MHS1; dbSNP:rs193922812)"
FT                   /evidence="ECO:0000269|PubMed:15448513"
FT                   /id="VAR_045727"
FT   VARIANT         2452
FT                   /note="R -> W (in MHS1 and KDS; dbSNP:rs118192124)"
FT                   /evidence="ECO:0000269|PubMed:10823104,
FT                   ECO:0000269|PubMed:12059893, ECO:0000269|PubMed:14985404,
FT                   ECO:0000269|PubMed:21514828"
FT                   /id="VAR_045728"
FT   VARIANT         2454
FT                   /note="R -> C (in MHS1; induces an increase sensitivity to
FT                   caffeine; increases calcium-induced calcium release
FT                   activity; dbSNP:rs193922816)"
FT                   /evidence="ECO:0000269|PubMed:10612851,
FT                   ECO:0000269|PubMed:12411788, ECO:0000305|PubMed:16163667,
FT                   ECO:0000305|PubMed:27586648"
FT                   /id="VAR_008975"
FT   VARIANT         2454
FT                   /note="R -> H (in MHS1; severe form; increases
FT                   calcium-induced calcium release activity;
FT                   dbSNP:rs118192122)"
FT                   /evidence="ECO:0000269|PubMed:10051009,
FT                   ECO:0000269|PubMed:10823104, ECO:0000269|PubMed:11575529,
FT                   ECO:0000269|PubMed:12059893, ECO:0000269|PubMed:12709367,
FT                   ECO:0000269|PubMed:15448513, ECO:0000269|PubMed:23558838,
FT                   ECO:0000305|PubMed:16163667, ECO:0000305|PubMed:27586648"
FT                   /id="VAR_008976"
FT   VARIANT         2458
FT                   /note="R -> C (in MHS1; dbSNP:rs28933397)"
FT                   /evidence="ECO:0000269|PubMed:12208234,
FT                   ECO:0000269|PubMed:16163667, ECO:0000269|PubMed:9450902,
FT                   ECO:0000305|PubMed:27586648"
FT                   /id="VAR_008977"
FT   VARIANT         2458
FT                   /note="R -> H (in MHS1; dbSNP:rs121918594)"
FT                   /evidence="ECO:0000269|PubMed:14985404,
FT                   ECO:0000269|PubMed:9450902, ECO:0000305|PubMed:27586648"
FT                   /id="VAR_008978"
FT   VARIANT         2508
FT                   /note="R -> C (in MHS1, CCD and KDS; increases sensitivity
FT                   to caffeine and 4-chloro-m-cresol; increases
FT                   calcium-induced calcium release activity;
FT                   dbSNP:rs118192178)"
FT                   /evidence="ECO:0000269|PubMed:19685112,
FT                   ECO:0000269|PubMed:27918309, ECO:0000305|PubMed:27586648"
FT                   /id="VAR_075399"
FT   VARIANT         2508
FT                   /note="R -> G (in CCD; increases sensitivity to caffeine
FT                   and 4-chloro-m-cresol; dbSNP:rs118192178)"
FT                   /evidence="ECO:0000269|PubMed:20142353,
FT                   ECO:0000269|PubMed:26381711"
FT                   /id="VAR_068516"
FT   VARIANT         2508
FT                   /note="R -> H (in MHS1; increases sensitivity to caffeine
FT                   and 4-chloro-m-cresol; increases calcium-induced calcium
FT                   release activity; dbSNP:rs193922818)"
FT                   /evidence="ECO:0000269|PubMed:26381711,
FT                   ECO:0000305|PubMed:27586648"
FT                   /id="VAR_077683"
FT   VARIANT         2509
FT                   /note="V -> I (in dbSNP:rs2071088)"
FT                   /id="VAR_051891"
FT   VARIANT         2550
FT                   /note="L -> V (in dbSNP:rs193922821)"
FT                   /evidence="ECO:0000269|PubMed:1354642,
FT                   ECO:0000269|PubMed:19191329, ECO:0000269|PubMed:8661021"
FT                   /id="VAR_058570"
FT   VARIANT         2593
FT                   /note="R -> G (in MHS1; dbSNP:rs756685891)"
FT                   /evidence="ECO:0000269|PubMed:20681998"
FT                   /id="VAR_071743"
FT   VARIANT         2627
FT                   /note="V -> M (in MHS1)"
FT                   /evidence="ECO:0000269|PubMed:24013571"
FT                   /id="VAR_071744"
FT   VARIANT         2676
FT                   /note="R -> W (associated in cis with S-2787; may be
FT                   associated with susceptibility to malignant hyperthermia;
FT                   dbSNP:rs193922826)"
FT                   /evidence="ECO:0000269|PubMed:14732627,
FT                   ECO:0000269|PubMed:16163667, ECO:0000269|PubMed:19191329"
FT                   /id="VAR_045729"
FT   VARIANT         2730
FT                   /note="D -> G (in MHS1; dbSNP:rs112196644)"
FT                   /evidence="ECO:0000269|PubMed:19191329"
FT                   /id="VAR_058571"
FT   VARIANT         2776
FT                   /note="S -> F (in KDS; unknown pathological significance;
FT                   dbSNP:rs147707463)"
FT                   /evidence="ECO:0000269|PubMed:21514828"
FT                   /id="VAR_086257"
FT   VARIANT         2779
FT                   /note="E -> K (in dbSNP:rs2915952)"
FT                   /id="VAR_051892"
FT   VARIANT         2787
FT                   /note="T -> S (associated in cis with W-2676; may be
FT                   associated with susceptibility to malignant hyperthermia;
FT                   dbSNP:rs35180584)"
FT                   /evidence="ECO:0000269|PubMed:14732627,
FT                   ECO:0000269|PubMed:16163667, ECO:0000269|PubMed:19191329"
FT                   /id="VAR_045730"
FT   VARIANT         2880
FT                   /note="E -> K (in MHS1; dbSNP:rs112772310)"
FT                   /evidence="ECO:0000269|PubMed:19191329"
FT                   /id="VAR_058572"
FT   VARIANT         2963
FT                   /note="L -> P (in CCD; dbSNP:rs756870293)"
FT                   /evidence="ECO:0000269|PubMed:27234031"
FT                   /id="VAR_076568"
FT   VARIANT         2976
FT                   /note="H -> Y"
FT                   /evidence="ECO:0000269|PubMed:20681998"
FT                   /id="VAR_071745"
FT   VARIANT         3118
FT                   /note="A -> V (in dbSNP:rs2915960)"
FT                   /id="VAR_045731"
FT   VARIANT         3217
FT                   /note="S -> P (in MHS1; dbSNP:rs113422327)"
FT                   /evidence="ECO:0000269|PubMed:19191329"
FT                   /id="VAR_058573"
FT   VARIANT         3238
FT                   /note="E -> G (in CCD; unknown pathological significance;
FT                   dbSNP:rs200950673)"
FT                   /evidence="ECO:0000269|PubMed:23558838"
FT                   /id="VAR_071746"
FT   VARIANT         3290
FT                   /note="E -> K (in MHS1; dbSNP:rs112151058)"
FT                   /evidence="ECO:0000269|PubMed:19191329"
FT                   /id="VAR_058574"
FT   VARIANT         3326
FT                   /note="N -> K (in MMDO; dbSNP:rs367543057)"
FT                   /evidence="ECO:0000269|PubMed:20583297"
FT                   /id="VAR_063848"
FT   VARIANT         3360
FT                   /note="P -> Q"
FT                   /evidence="ECO:0000269|PubMed:20681998"
FT                   /id="VAR_071747"
FT   VARIANT         3366
FT                   /note="R -> H (in CCD; dbSNP:rs137932199)"
FT                   /evidence="ECO:0000269|PubMed:21674524"
FT                   /id="VAR_068517"
FT   VARIANT         3402
FT                   /note="C -> G (in MMDO; dbSNP:rs367543058)"
FT                   /evidence="ECO:0000269|PubMed:20583297"
FT                   /id="VAR_063849"
FT   VARIANT         3410
FT                   /note="P -> Q (in MHS1)"
FT                   /evidence="ECO:0000269|PubMed:20681998"
FT                   /id="VAR_071748"
FT   VARIANT         3501
FT                   /note="D -> Y (in MHS1; dbSNP:rs763259167)"
FT                   /evidence="ECO:0000269|PubMed:20681998"
FT                   /id="VAR_071749"
FT   VARIANT         3527
FT                   /note="P -> S (in CCD; autosomal recessive form;
FT                   dbSNP:rs118192164)"
FT                   /evidence="ECO:0000269|PubMed:12112081"
FT                   /id="VAR_045732"
FT   VARIANT         3539
FT                   /note="R -> H (in CCD; autosomal recessive form;
FT                   dbSNP:rs143987857)"
FT                   /evidence="ECO:0000269|PubMed:18253926"
FT                   /id="VAR_045733"
FT   VARIANT         3583
FT                   /note="E -> Q (in dbSNP:rs55876273)"
FT                   /evidence="ECO:0000269|PubMed:19191329"
FT                   /id="VAR_058575"
FT   VARIANT         3711
FT                   /note="T -> R (in MHS1; unknown pathological significance;
FT                   dbSNP:rs375915752)"
FT                   /evidence="ECO:0000269|PubMed:23558838"
FT                   /id="VAR_071750"
FT   VARIANT         3756
FT                   /note="Q -> E (in dbSNP:rs4802584)"
FT                   /evidence="ECO:0000269|PubMed:11928716,
FT                   ECO:0000269|PubMed:19191329"
FT                   /id="VAR_032916"
FT   VARIANT         3772
FT                   /note="R -> Q (in CCD; autosomal recessive form;
FT                   dbSNP:rs193922839)"
FT                   /evidence="ECO:0000269|PubMed:18253926"
FT                   /id="VAR_045734"
FT   VARIANT         3772
FT                   /note="R -> W (in MHS1; dbSNP:rs763112609)"
FT                   /evidence="ECO:0000269|PubMed:19191329"
FT                   /id="VAR_058576"
FT   VARIANT         3806
FT                   /note="G -> R (in MHS1; dbSNP:rs111565359)"
FT                   /evidence="ECO:0000269|PubMed:19191329"
FT                   /id="VAR_058577"
FT   VARIANT         3916
FT                   /note="I -> M (in MHS1; dbSNP:rs193922840)"
FT                   /evidence="ECO:0000269|PubMed:12411788,
FT                   ECO:0000269|PubMed:16163667"
FT                   /id="VAR_045735"
FT   VARIANT         3933
FT                   /note="Y -> C (in CCD and MHS1; dbSNP:rs147136339)"
FT                   /evidence="ECO:0000269|PubMed:20681998,
FT                   ECO:0000269|PubMed:21674524"
FT                   /id="VAR_068518"
FT   VARIANT         4136
FT                   /note="R -> S (in MHS1; dbSNP:rs193922849)"
FT                   /evidence="ECO:0000269|PubMed:12208234"
FT                   /id="VAR_045736"
FT   VARIANT         4178
FT                   /note="G -> V (in MHS1; unknown pathological significance;
FT                   dbSNP:rs1568576165)"
FT                   /evidence="ECO:0000269|PubMed:23558838"
FT                   /id="VAR_071751"
FT   VARIANT         4214..4216
FT                   /note="Missing (in CCD)"
FT                   /id="VAR_045737"
FT   VARIANT         4230
FT                   /note="M -> R (in MHS1; unknown pathological significance;
FT                   dbSNP:rs1568581848)"
FT                   /evidence="ECO:0000269|PubMed:23558838"
FT                   /id="VAR_071752"
FT   VARIANT         4234
FT                   /note="V -> L (in MHS1; dbSNP:rs193922852)"
FT                   /evidence="ECO:0000269|PubMed:12208234,
FT                   ECO:0000269|PubMed:24013571"
FT                   /id="VAR_045738"
FT   VARIANT         4493
FT                   /note="P -> A (in dbSNP:rs149455643)"
FT                   /evidence="ECO:0000269|PubMed:21674524"
FT                   /id="VAR_068519"
FT   VARIANT         4501
FT                   /note="P -> L (may be associated with susceptibility to
FT                   malignant hyperthermia; dbSNP:rs73933023)"
FT                   /evidence="ECO:0000269|PubMed:19191329"
FT                   /id="VAR_058578"
FT   VARIANT         4558
FT                   /note="R -> Q (in CCD; autosomal recessive form;
FT                   dbSNP:rs118192130)"
FT                   /evidence="ECO:0000269|PubMed:17226826,
FT                   ECO:0000269|PubMed:18253926"
FT                   /id="VAR_045739"
FT   VARIANT         4637
FT                   /note="T -> A (in CCD; dbSNP:rs118192166)"
FT                   /evidence="ECO:0000269|PubMed:11113224"
FT                   /id="VAR_045740"
FT   VARIANT         4637
FT                   /note="T -> I (in core/rod disease; dbSNP:rs118192134)"
FT                   /evidence="ECO:0000269|PubMed:12565913"
FT                   /id="VAR_045741"
FT   VARIANT         4638
FT                   /note="G -> D (in CCD; dbSNP:rs118192135)"
FT                   /evidence="ECO:0000269|PubMed:12565913,
FT                   ECO:0000269|PubMed:14985404"
FT                   /id="VAR_045742"
FT   VARIANT         4647..4648
FT                   /note="Missing (in CCD)"
FT                   /evidence="ECO:0000269|PubMed:11709545"
FT                   /id="VAR_045743"
FT   VARIANT         4650
FT                   /note="L -> P (in CCD; autosomal recessive form;
FT                   dbSNP:rs118192138)"
FT                   /evidence="ECO:0000269|PubMed:12937085"
FT                   /id="VAR_045744"
FT   VARIANT         4651
FT                   /note="H -> P (in CCD; dbSNP:rs118192139)"
FT                   /evidence="ECO:0000269|PubMed:12565913"
FT                   /id="VAR_045745"
FT   VARIANT         4668
FT                   /note="P -> S (in dbSNP:rs193922863)"
FT                   /evidence="ECO:0000269|PubMed:11928716"
FT                   /id="VAR_045746"
FT   VARIANT         4684
FT                   /note="F -> S (in MHS1; dbSNP:rs193922864)"
FT                   /evidence="ECO:0000269|PubMed:16163667"
FT                   /id="VAR_045747"
FT   VARIANT         4724
FT                   /note="K -> Q (in CCD; autosomal recessive form;
FT                   dbSNP:rs118192141)"
FT                   /evidence="ECO:0000269|PubMed:12937085"
FT                   /id="VAR_045748"
FT   VARIANT         4737
FT                   /note="R -> Q (in MHS1; dbSNP:rs193922868)"
FT                   /evidence="ECO:0000269|PubMed:16163667"
FT                   /id="VAR_045749"
FT   VARIANT         4737
FT                   /note="R -> W (in MHS1; unknown pathological significance;
FT                   slightly increases Ca(2+) release in response to
FT                   4-chloro-m-cresol; dbSNP:rs193922867)"
FT                   /evidence="ECO:0000269|PubMed:12208234,
FT                   ECO:0000269|PubMed:16163667, ECO:0000269|PubMed:26631338"
FT                   /id="VAR_045750"
FT   VARIANT         4743
FT                   /note="G -> D (in CCD; dbSNP:rs193922869)"
FT                   /evidence="ECO:0000269|PubMed:21674524"
FT                   /id="VAR_068520"
FT   VARIANT         4793
FT                   /note="L -> P (in CCD; dbSNP:rs118192179)"
FT                   /evidence="ECO:0000269|PubMed:11709545"
FT                   /id="VAR_045751"
FT   VARIANT         4796
FT                   /note="Y -> C (in CCD; dbSNP:rs118192167)"
FT                   /evidence="ECO:0000269|PubMed:11709545"
FT                   /id="VAR_045752"
FT   VARIANT         4806
FT                   /note="N -> D (in CCD; dbSNP:rs886039586)"
FT                   /evidence="ECO:0000269|PubMed:27234031"
FT                   /id="VAR_076569"
FT   VARIANT         4814
FT                   /note="L -> F (in CCD; dbSNP:rs118192142)"
FT                   /evidence="ECO:0000269|PubMed:14985404"
FT                   /id="VAR_045753"
FT   VARIANT         4824
FT                   /note="L -> P (in MHS1; dbSNP:rs193922874)"
FT                   /evidence="ECO:0000269|PubMed:14985404,
FT                   ECO:0000269|PubMed:15448513"
FT                   /id="VAR_045754"
FT   VARIANT         4825
FT                   /note="R -> C (in CCD; dbSNP:rs118192180)"
FT                   /evidence="ECO:0000269|PubMed:11709545"
FT                   /id="VAR_045755"
FT   VARIANT         4826
FT                   /note="T -> I (in MHS1; dbSNP:rs121918595)"
FT                   /evidence="ECO:0000269|PubMed:10888602,
FT                   ECO:0000269|PubMed:16163667"
FT                   /id="VAR_045756"
FT   VARIANT         4837
FT                   /note="Q -> E (in MHS1; unknown pathological significance;
FT                   dbSNP:rs1568604577)"
FT                   /evidence="ECO:0000269|PubMed:23558838"
FT                   /id="VAR_071753"
FT   VARIANT         4838
FT                   /note="L -> V (in MHS1; dbSNP:rs193922878)"
FT                   /evidence="ECO:0000269|PubMed:11928716,
FT                   ECO:0000269|PubMed:16163667, ECO:0000269|PubMed:19191329"
FT                   /id="VAR_045757"
FT   VARIANT         4842
FT                   /note="V -> M (in CCD; autosomal recessive form;
FT                   dbSNP:rs193922879)"
FT                   /evidence="ECO:0000269|PubMed:18253926"
FT                   /id="VAR_045758"
FT   VARIANT         4846
FT                   /note="A -> V (in CCD; autosomal recessive form;
FT                   dbSNP:rs118192143)"
FT                   /evidence="ECO:0000269|PubMed:17204054,
FT                   ECO:0000269|PubMed:17226826"
FT                   /id="VAR_045759"
FT   VARIANT         4849
FT                   /note="V -> I (in MHS1 and CCD; autosomal recessive form;
FT                   dbSNP:rs118192168)"
FT                   /evidence="ECO:0000269|PubMed:12136074,
FT                   ECO:0000269|PubMed:16163667, ECO:0000269|PubMed:17226826,
FT                   ECO:0000269|PubMed:18253926"
FT                   /id="VAR_045760"
FT   VARIANT         4860
FT                   /note="Missing (in CCD; dbSNP:rs118192145)"
FT                   /evidence="ECO:0000269|PubMed:11709545"
FT                   /id="VAR_045761"
FT   VARIANT         4861
FT                   /note="R -> C (in CCD; dbSNP:rs118192181)"
FT                   /evidence="ECO:0000269|PubMed:12565913,
FT                   ECO:0000269|PubMed:17226826"
FT                   /id="VAR_045762"
FT   VARIANT         4861
FT                   /note="R -> H (in CCD and MHS1; release of calcium from
FT                   intracellular stores in the absence of any pharmacological
FT                   activator of RYR; dbSNP:rs63749869)"
FT                   /evidence="ECO:0000269|PubMed:11709545,
FT                   ECO:0000269|PubMed:11741831, ECO:0000269|PubMed:12565913,
FT                   ECO:0000269|PubMed:14670767, ECO:0000269|PubMed:14985404,
FT                   ECO:0000269|PubMed:17226826, ECO:0000269|PubMed:23558838,
FT                   ECO:0000269|PubMed:24561095"
FT                   /id="VAR_045763"
FT   VARIANT         4863..4869
FT                   /note="FYNKSED -> Y (in CCD)"
FT                   /id="VAR_045764"
FT   VARIANT         4864
FT                   /note="Y -> C (in CCD; dbSNP:rs118192146)"
FT                   /evidence="ECO:0000269|PubMed:14670767"
FT                   /id="VAR_045765"
FT   VARIANT         4876
FT                   /note="K -> R (in MHS1; dbSNP:rs113210953)"
FT                   /evidence="ECO:0000269|PubMed:16163667,
FT                   ECO:0000269|PubMed:19191329"
FT                   /id="VAR_045766"
FT   VARIANT         4882
FT                   /note="T -> M (in CCD; dbSNP:rs193922884)"
FT                   /evidence="ECO:0000269|PubMed:18312400"
FT                   /id="VAR_068521"
FT   VARIANT         4891
FT                   /note="G -> R (in CCD; dbSNP:rs118192149)"
FT                   /evidence="ECO:0000269|PubMed:11741831"
FT                   /id="VAR_045767"
FT   VARIANT         4893
FT                   /note="R -> Q (in CCD; dbSNP:rs118192151)"
FT                   /evidence="ECO:0000269|PubMed:12565913"
FT                   /id="VAR_045768"
FT   VARIANT         4893
FT                   /note="R -> W (in CCD; release of calcium from
FT                   intracellular stores in the absence of any pharmacological
FT                   activator of RYR; smaller thapsigargin-sensitive
FT                   intracellular calcium stores; normal sensitivity of the
FT                   calcium release to the RYR inhibitor dantrolene;
FT                   dbSNP:rs118192150)"
FT                   /evidence="ECO:0000269|PubMed:11709545,
FT                   ECO:0000269|PubMed:11741831, ECO:0000269|PubMed:14670767"
FT                   /id="VAR_045769"
FT   VARIANT         4897
FT                   /note="G -> A (in CCD)"
FT                   /evidence="ECO:0000269|PubMed:24561095"
FT                   /id="VAR_071754"
FT   VARIANT         4897
FT                   /note="G -> V (in CCD; dbSNP:rs118192148)"
FT                   /evidence="ECO:0000269|PubMed:17226826"
FT                   /id="VAR_045770"
FT   VARIANT         4898
FT                   /note="I -> T (in CCD; severe phenotype;
FT                   dbSNP:rs118192170)"
FT                   /evidence="ECO:0000269|PubMed:10097181,
FT                   ECO:0000269|PubMed:11709545, ECO:0000269|PubMed:11741831,
FT                   ECO:0000269|PubMed:12565913, ECO:0000269|PubMed:24561095"
FT                   /id="VAR_045771"
FT   VARIANT         4899
FT                   /note="G -> E (in CCD; dbSNP:rs118192183)"
FT                   /evidence="ECO:0000269|PubMed:11709545,
FT                   ECO:0000269|PubMed:12937085"
FT                   /id="VAR_045772"
FT   VARIANT         4899
FT                   /note="G -> R (in CCD; release of calcium from
FT                   intracellular stores in the absence of any pharmacological
FT                   activator of RYR; smaller thapsigargin-sensitive
FT                   intracellular calcium stores; normal sensitivity of the
FT                   calcium release to the RYR inhibitor dantrolene;
FT                   dbSNP:rs193922891)"
FT                   /evidence="ECO:0000269|PubMed:11741831"
FT                   /id="VAR_045773"
FT   VARIANT         4906
FT                   /note="A -> G (in MHS1; unknown pathological significance;
FT                   dbSNP:rs118192153)"
FT                   /evidence="ECO:0000269|PubMed:23558838"
FT                   /id="VAR_071755"
FT   VARIANT         4906
FT                   /note="A -> V (in CCD; dbSNP:rs118192153)"
FT                   /evidence="ECO:0000269|PubMed:11741831"
FT                   /id="VAR_045774"
FT   VARIANT         4914
FT                   /note="R -> G (in CCD; dbSNP:rs118192184)"
FT                   /evidence="ECO:0000269|PubMed:11709545,
FT                   ECO:0000269|PubMed:12565913"
FT                   /id="VAR_045775"
FT   VARIANT         4914
FT                   /note="R -> T (in CCD; dbSNP:rs118192154)"
FT                   /evidence="ECO:0000269|PubMed:12565913,
FT                   ECO:0000269|PubMed:17226826"
FT                   /id="VAR_045776"
FT   VARIANT         4927..4928
FT                   /note="Missing (in CCD)"
FT                   /evidence="ECO:0000269|PubMed:12565913"
FT                   /id="VAR_045777"
FT   VARIANT         4938
FT                   /note="I -> M (in CCD; dbSNP:rs118192159)"
FT                   /evidence="ECO:0000269|PubMed:14985404"
FT                   /id="VAR_045778"
FT   VARIANT         4938
FT                   /note="I -> T (in MHS1; dbSNP:rs111657878)"
FT                   /evidence="ECO:0000269|PubMed:19191329"
FT                   /id="VAR_058579"
FT   VARIANT         4939
FT                   /note="D -> E (in MHS1; dbSNP:rs193922895)"
FT                   /evidence="ECO:0000269|PubMed:14985404,
FT                   ECO:0000269|PubMed:16163667"
FT                   /id="VAR_045779"
FT   VARIANT         4940
FT                   /note="A -> T (in CCD; dbSNP:rs118192158)"
FT                   /evidence="ECO:0000269|PubMed:12565913,
FT                   ECO:0000269|PubMed:14670767"
FT                   /id="VAR_045780"
FT   VARIANT         4942
FT                   /note="G -> V (in MHS1; dbSNP:rs193922896)"
FT                   /evidence="ECO:0000269|PubMed:12208234"
FT                   /id="VAR_045781"
FT   VARIANT         4973
FT                   /note="P -> L (in MHS1; dbSNP:rs146876145)"
FT                   /evidence="ECO:0000269|PubMed:12208234,
FT                   ECO:0000269|PubMed:12411788, ECO:0000269|PubMed:16163667"
FT                   /id="VAR_045782"
FT   MUTAGEN         522
FT                   /note="Y->C: Increases calcium-induced calcium release
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:26115329"
FT   MUTAGEN         2508
FT                   /note="R->K: Increases sensitivity to caffeine and
FT                   4-chloro-m-cresol."
FT                   /evidence="ECO:0000269|PubMed:26381711"
FT   MUTAGEN         2508
FT                   /note="R->S: Increases sensitivity to caffeine and
FT                   4-chloro-m-cresol."
FT                   /evidence="ECO:0000269|PubMed:26381711"
FT   CONFLICT        1365..1368
FT                   /note="GEAQ -> RGA (in Ref. 1; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2324
FT                   /note="N -> K (in Ref. 1; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2840
FT                   /note="R -> A (in Ref. 1; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        3380
FT                   /note="R -> A (in Ref. 1; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   HELIX           864..887
FT                   /evidence="ECO:0007829|PDB:6UHS"
FT   TURN            898..901
FT                   /evidence="ECO:0007829|PDB:6UHS"
FT   HELIX           909..911
FT                   /evidence="ECO:0007829|PDB:6UHS"
FT   HELIX           914..933
FT                   /evidence="ECO:0007829|PDB:6UHS"
FT   STRAND          936..940
FT                   /evidence="ECO:0007829|PDB:6UHS"
SQ   SEQUENCE   5038 AA;  565176 MW;  EC32277F4885CC7F CRC64;
     MGDAEGEDEV QFLRTDDEVV LQCSATVLKE QLKLCLAAEG FGNRLCFLEP TSNAQNVPPD
     LAICCFVLEQ SLSVRALQEM LANTVEAGVE SSQGGGHRTL LYGHAILLRH AHSRMYLSCL
     TTSRSMTDKL AFDVGLQEDA TGEACWWTMH PASKQRSEGE KVRVGDDIIL VSVSSERYLH
     LSTASGELQV DASFMQTLWN MNPICSRCEE GFVTGGHVLR LFHGHMDECL TISPADSDDQ
     RRLVYYEGGA VCTHARSLWR LEPLRISWSG SHLRWGQPLR VRHVTTGQYL ALTEDQGLVV
     VDASKAHTKA TSFCFRISKE KLDVAPKRDV EGMGPPEIKY GESLCFVQHV ASGLWLTYAA
     PDPKALRLGV LKKKAMLHQE GHMDDALSLT RCQQEESQAA RMIHSTNGLY NQFIKSLDSF
     SGKPRGSGPP AGTALPIEGV ILSLQDLIIY FEPPSEDLQH EEKQSKLRSL RNRQSLFQEE
     GMLSMVLNCI DRLNVYTTAA HFAEFAGEEA AESWKEIVNL LYELLASLIR GNRSNCALFS
     TNLDWLVSKL DRLEASSGIL EVLYCVLIES PEVLNIIQEN HIKSIISLLD KHGRNHKVLD
     VLCSLCVCNG VAVRSNQDLI TENLLPGREL LLQTNLINYV TSIRPNIFVG RAEGTTQYSK
     WYFEVMVDEV TPFLTAQATH LRVGWALTEG YTPYPGAGEG WGGNGVGDDL YSYGFDGLHL
     WTGHVARPVT SPGQHLLAPE DVISCCLDLS VPSISFRING CPVQGVFESF NLDGLFFPVV
     SFSAGVKVRF LLGGRHGEFK FLPPPGYAPC HEAVLPRERL HLEPIKEYRR EGPRGPHLVG
     PSRCLSHTDF VPCPVDTVQI VLPPHLERIR EKLAENIHEL WALTRIEQGW TYGPVRDDNK
     RLHPCLVDFH SLPEPERNYN LQMSGETLKT LLALGCHVGM ADEKAEDNLK KTKLPKTYMM
     SNGYKPAPLD LSHVRLTPAQ TTLVDRLAEN GHNVWARDRV GQGWSYSAVQ DIPARRNPRL
     VPYRLLDEAT KRSNRDSLCQ AVRTLLGYGY NIEPPDQEPS QVENQSRCDR VRIFRAEKSY
     TVQSGRWYFE FEAVTTGEMR VGWARPELRP DVELGADELA YVFNGHRGQR WHLGSEPFGR
     PWQPGDVVGC MIDLTENTII FTLNGEVLMS DSGSETAFRE IEIGDGFLPV CSLGPGQVGH
     LNLGQDVSSL RFFAICGLQE GFEPFAINMQ RPVTTWFSKG LPQFEPVPLE HPHYEVSRVD
     GTVDTPPCLR LTHRTWGSQN SLVEMLFLRL SLPVQFHQHF RCTAGATPLA PPGLQPPAED
     EARAAEPDPD YENLRRSAGG WSEAENGKEG TAKEGAPGGT PQAGGEAQPA RAENEKDATT
     EKNKKRGFLF KAKKVAMMTQ PPATPTLPRL PHDVVPADNR DDPEIILNTT TYYYSVRVFA
     GQEPSCVWAG WVTPDYHQHD MSFDLSKVRV VTVTMGDEQG NVHSSLKCSN CYMVWGGDFV
     SPGQQGRISH TDLVIGCLVD LATGLMTFTA NGKESNTFFQ VEPNTKLFPA VFVLPTHQNV
     IQFELGKQKN IMPLSAAMFQ SERKNPAPQC PPRLEMQMLM PVSWSRMPNH FLQVETRRAG
     ERLGWAVQCQ EPLTMMALHI PEENRCMDIL ELSERLDLQR FHSHTLRLYR AVCALGNNRV
     AHALCSHVDQ AQLLHALEDA HLPGPLRAGY YDLLISIHLE SACRSRRSML SEYIVPLTPE
     TRAITLFPPG RSTENGHPRH GLPGVGVTTS LRPPHHFSPP CFVAALPAAG AAEAPARLSP
     AIPLEALRDK ALRMLGEAVR DGGQHARDPV GGSVEFQFVP VLKLVSTLLV MGIFGDEDVK
     QILKMIEPEV FTEEEEEEDE EEEGEEEDEE EKEEDEEETA QEKEDEEKEE EEAAEGEKEE
     GLEEGLLQMK LPESVKLQMC HLLEYFCDQE LQHRVESLAA FAERYVDKLQ ANQRSRYGLL
     IKAFSMTAAE TARRTREFRS PPQEQINMLL QFKDGTDEED CPLPEEIRQD LLDFHQDLLA
     HCGIQLDGEE EEPEEETTLG SRLMSLLEKV RLVKKKEEKP EEERSAEESK PRSLQELVSH
     MVVRWAQEDF VQSPELVRAM FSLLHRQYDG LGELLRALPR AYTISPSSVE DTMSLLECLG
     QIRSLLIVQM GPQEENLMIQ SIGNIMNNKV FYQHPNLMRA LGMHETVMEV MVNVLGGGES
     KEIRFPKMVT SCCRFLCYFC RISRQNQRSM FDHLSYLLEN SGIGLGMQGS TPLDVAAASV
     IDNNELALAL QEQDLEKVVS YLAGCGLQSC PMLVAKGYPD IGWNPCGGER YLDFLRFAVF
     VNGESVEENA NVVVRLLIRK PECFGPALRG EGGSGLLAAI EEAIRISEDP ARDGPGIRRD
     RRREHFGEEP PEENRVHLGH AIMSFYAALI DLLGRCAPEM HLIQAGKGEA LRIRAILRSL
     VPLEDLVGII SLPLQIPTLG KDGALVQPKM SASFVPDHKA SMVLFLDRVY GIENQDFLLH
     VLDVGFLPDM RAAASLDTAT FSTTEMALAL NRYLCLAVLP LITKCAPLFA GTEHRAIMVD
     SMLHTVYRLS RGRSLTKAQR DVIEDCLMSL CRYIRPSMLQ HLLRRLVFDV PILNEFAKMP
     LKLLTNHYER CWKYYCLPTG WANFGVTSEE ELHLTRKLFW GIFDSLAHKK YDPELYRMAM
     PCLCAIAGAL PPDYVDASYS SKAEKKATVD AEGNFDPRPV ETLNVIIPEK LDSFINKFAE
     YTHEKWAFDK IQNNWSYGEN IDEELKTHPM LRPYKTFSEK DKEIYRWPIK ESLKAMIAWE
     WTIEKAREGE EEKTEKKKTR KISQSAQTYD PREGYNPQPP DLSAVTLSRE LQAMAEQLAE
     NYHNTWGRKK KQELEAKGGG THPLLVPYDT LTAKEKARDR EKAQELLKFL QMNGYAVTRG
     LKDMELDSSS IEKRFAFGFL QQLLRWMDIS QEFIAHLEAV VSSGRVEKSP HEQEIKFFAK
     ILLPLINQYF TNHCLYFLST PAKVLGSGGH ASNKEKEMIT SLFCKLAALV RHRVSLFGTD
     APAVVNCLHI LARSLDARTV MKSGPEIVKA GLRSFFESAS EDIEKMVENL RLGKVSQART
     QVKGVGQNLT YTTVALLPVL TTLFQHIAQH QFGDDVILDD VQVSCYRTLC SIYSLGTTKN
     TYVEKLRPAL GECLARLAAA MPVAFLEPQL NEYNACSVYT TKSPRERAIL GLPNSVEEMC
     PDIPVLERLM ADIGGLAESG ARYTEMPHVI EITLPMLCSY LPRWWERGPE APPSALPAGA
     PPPCTAVTSD HLNSLLGNIL RIIVNNLGID EASWMKRLAV FAQPIVSRAR PELLQSHFIP
     TIGRLRKRAG KVVSEEEQLR LEAKAEAQEG ELLVRDEFSV LCRDLYALYP LLIRYVDNNR
     AQWLTEPNPS AEELFRMVGE IFIYWSKSHN FKREEQNFVV QNEINNMSFL TADNKSKMAK
     AGDIQSGGSD QERTKKKRRG DRYSVQTSLI VATLKKMLPI GLNMCAPTDQ DLITLAKTRY
     ALKDTDEEVR EFLHNNLHLQ GKVEGSPSLR WQMALYRGVP GREEDADDPE KIVRRVQEVS
     AVLYYLDQTE HPYKSKKAVW HKLLSKQRRR AVVACFRMTP LYNLPTHRAC NMFLESYKAA
     WILTEDHSFE DRMIDDLSKA GEQEEEEEEV EEKKPDPLHQ LVLHFSRTAL TEKSKLDEDY
     LYMAYADIMA KSCHLEEGGE NGEAEEEVEV SFEEKQMEKQ RLLYQQARLH TRGAAEMVLQ
     MISACKGETG AMVSSTLKLG ISILNGGNAE VQQKMLDYLK DKKEVGFFQS IQALMQTCSV
     LDLNAFERQN KAEGLGMVNE DGTVINRQNG EKVMADDEFT QDLFRFLQLL CEGHNNDFQN
     YLRTQTGNTT TINIIICTVD YLLRLQESIS DFYWYYSGKD VIEEQGKRNF SKAMSVAKQV
     FNSLTEYIQG PCTGNQQSLA HSRLWDAVVG FLHVFAHMMM KLAQDSSQIE LLKELLDLQK
     DMVVMLLSLL EGNVVNGMIA RQMVDMLVES SSNVEMILKF FDMFLKLKDI VGSEAFQDYV
     TDPRGLISKK DFQKAMDSQK QFSGPEIQFL LSCSEADENE MINCEEFANR FQEPARDIGF
     NVAVLLTNLS EHVPHDPRLH NFLELAESIL EYFRPYLGRI EIMGASRRIE RIYFEISETN
     RAQWEMPQVK ESKRQFIFDV VNEGGEAEKM ELFVSFCEDT IFEMQIAAQI SEPEGEPETD
     EDEGAGAAEA GAEGAEEGAA GLEGTAATAA AGATARVVAA AGRALRGLSY RSLRRRVRRL
     RRLTAREAAT AVAALLWAAV TRAGAAGAGA AAGALGLLWG SLFGGGLVEG AKKVTVTELL
     AGMPDPTSDE VHGEQPAGPG GDADGEGASE GAGDAAEGAG DEEEAVHEAG PGGADGAVAV
     TDGGPFRPEG AGGLGDMGDT TPAEPPTPEG SPILKRKLGV DGVEEELPPE PEPEPEPELE
     PEKADAENGE KEEVPEPTPE PPKKQAPPSP PPKKEEAGGE FWGELEVQRV KFLNYLSRNF
     YTLRFLALFL AFAINFILLF YKVSDSPPGE DDMEGSAAGD VSGAGSGGSS GWGLGAGEEA
     EGDEDENMVY YFLEESTGYM EPALRCLSLL HTLVAFLCII GYNCLKVPLV IFKREKELAR
     KLEFDGLYIT EQPEDDDVKG QWDRLVLNTP SFPSNYWDKF VKRKVLDKHG DIYGRERIAE
     LLGMDLATLE ITAHNERKPN PPPGLLTWLM SIDVKYQIWK FGVIFTDNSF LYLGWYMVMS
     LLGHYNNFFF AAHLLDIAMG VKTLRTILSS VTHNGKQLVM TVGLLAVVVY LYTVVAFNFF
     RKFYNKSEDE DEPDMKCDDM MTCYLFHMYV GVRAGGGIGD EIEDPAGDEY ELYRVVFDIT
     FFFFVIVILL AIIQGLIIDA FGELRDQQEQ VKEDMETKCF ICGIGSDYFD TTPHGFETHT
     LEEHNLANYM FFLMYLINKD ETEHTGQESY VWKMYQERCW DFFPAGDCFR KQYEDQLS
//
